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Abstract
Retention of a drug delivery system in the stomach is one way of improving and 
controlling the absorption of drugs that have an absorption window in the upper small 
intestine. By releasing the drug at a controlled rate across this main absorption site for a 
prolonged period, improved blood levels, and therefore better tolerated dosage regimes, 
can be achieved.
Gas-powered floating delivery systems have emerged as one of the most promising 
of the gastric retention methods currently in development. However, at present, gas- 
powered floating dosage forms do not have a standardised battery of in vitro tests that are 
predicative of in vivo results. There is therefore a need for a rationalised approach to 
floating dosage form design, which will enable us to evolve a proper mechanistic 
understanding of the behaviour of such dosage forms, thus improving the accurate 
prediction of in vivo behaviour.
The most important factor to consider when designing floating dosage forms is the 
ability of the formulation to float upon the gastric fluids. It is also vital to quantitate the 
floating profile of the dosage form over a functional time period. An apparatus has 
therefore been developed that accurately measures the resultant weight of a dosage form at 
predetermined intervals over an elongated time period.
The controlled production of gas from a floating dosage form offers considerable 
benefits to the formulator. A novel in vitro pressure vessel, capable of assessing the real 
time production of gas from a formulation over a designated time period, has therefore 
been designed and tested.
The extent to which a polymer system swells upon hydration in vivo has a direct 
effect on the density of floating dosage forms. An in vitro method capable of accurately 
measuring the dynamic swelling of a dosage form has therefore been developed.
The apparatus have been extensively tested using a selection of manufactured gas 
powered floating dosage forms. The relationship between the parameters has been 
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7.7 Gastrointestinal transit and drug absorption
It is generally recognised that the main absorption site of drugs in humans is the 
small intestine, due to its high relative surface area and associated uptake sites (Davis et al, 
1986a). It has also been shown that the colon acts as an absorption site for some drugs 
such as theophylline (Yuen et al, 1993). Other drugs, such as ciprofloxacin, diazepam, 
frusemide and various ACE inhibitors, have been shown to have a small preferential site of 
absorption located in the upper small intestine, known as an “absorption window” (Harder 
et al, 1990; Chan et al 1994; Grass and Morehead, 1989). However, the extent of drug 
absorption in a segment of the GI tract depends on the rate of absorption, as well as the 
time available for the absorption to occur (Rouge et al, 1996).
When drugs with absorption windows are formulated in normal controlled release 
dosage forms, some of the drug will be released after the main absorption site has been 
passed, resulting in incomplete delivery. The delivery site has to therefore be controlled, 
in order to improve the absorption of certain drugs. It follows that the gastric residence 
time of a dosage form will markedly influence both the rate of absorption and the total 
absorption of many drugs.
As previously mentioned, for some drugs it may be preferential to target the colon 
for delivery. This would be the case if local action was required or for compounds such as 
peptides that would otherwise be metabolised in the small intestine. Indeed, delivery 
systems have been investigated that would allow colon specific targeting (Gliko-Kabir et al 
2000a and b).
1.2 Gastric emptying
The stomach is anatomically divided into three parts: fundus, body and antrum (or 
pylorus). The proximal stomach, made up of the fundus and body regions, serves as a 
reservoir for ingested materials while the distal region (antrum) is the major site of mixing 
motions, acting as a pump to accomplish gastric emptying.
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1.2.1 Postprandial emptying
The stomach has the ability to empty different meal constituents at different rates, 
even when they are ingested simultaneously (Christensen et al, 1985). Resistance to the 
flow of liquids across the pylorus is relatively small therefore they empty from the stomach 
rapidly. Resistance to digestible solids, however, is much greater, resulting in the need for 
solids to be broken down before they can be emptied from the stomach (Weiner et al,
1981). Any particles that are too large to pass through the pylorus are returned back into 
the distal stomach for further digestion as many times as is necessary. Indigestible solids 
larger than approximately 2mm are thought to be retained to some degree during the 
postprandial period (Kelly, 1981).
1.2.2 Interdigestive emptying
After the stomach has finished emptying the contents of a meal, all that remains is 
mucus, cellular debris and any indigestible solids over approximately 2mm in diameter. A 
special mechanism called the interdigestive myoelectric complex (IMMC or housekeeper 
wave) exists to flush out the contents of the fasted stomach (Code and Marlett, 1975). The 
complex occurs in four phases of differing activity. It is the 2nd and 3rd phases that are the 
most powerful, with contractions in phase 3 being powerful enough to sweep the fasting 
stomach contents out into the duodenum. In the fasted state the complex is thought to 
occur at roughly 2 hourly intervals, but the actual duration and onset of each cycle varies 
both inter and intra subject.
1.2.3 Factors affecting gastric emptying rate
Fatty acids are known to reduce the rate of gastric emptying. This is regulated by 
duodenojejunal receptors that are sensitive to fatty acids. The important factor in 
determining the degree of slowing is the chain length of the fatty acid. The 14-carbon 
chain myristic acid is known to have to the greatest effect (Hunt and Knox, 1968).
The number of calories delivered to the duodenum tends be at a constant rate of 
approximately 2 kcal/min (Brener et al, 1983). Therefore the greater the concentration of 
energy (kcal/ml) in the stomach contents, the less volume is transferred per minute to the
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duodenum. There are possibly duodenal receptors that are sensitive to the fatty acid anions 
produced during triglyceride digestion (Hunt, 1980).
Any increase in the acidity of the stomach contents also causes a decrease in 
stomach emptying rate. This is again due to duodenal receptors, which appear to maintain 
the pH of the duodenum at 6.5 (Hunt and Knox, 1972).
Some drugs are capable of having an effect on the rate of gastric emptying. 
Anticholinergics, antihistamines, tricyclic antidepressants, phenothiazines and 
propantheline have all been known to delay gastric emptying, which can be attributed to 
their antimuscarinic effects. Metoclopramide, cholinergics and nicotine have all been 
shown to increase emptying rate.
1.3 Gastric emptying of dosage forms
The gastric emptying of dosage forms were measured in early studies by employing 
X-ray examinations to follow the GI transit of radiopaque formulations (Wagner et al, 
1958). This method suffers from the modification of the dosage form’s characteristics 
which inevitably result from the incorporation of barium sulphate.
More recently the advent of gamma scintigraphy has enabled workers to compile 
useful information concerning the gastric emptying of various drug delivery systems 
(Bechgaard et al, 1985; Wilson and Hardy, 1985; Davis et al, 1986b; Sangekar et al, 1987).
The emptying of controlled release dosage forms from the stomach will depend 
upon the presence or absence of food and the size of the ingested system. Food influences 
the gastric retention time of dosage forms in that it delays the onset of the IMMC, thus any 
indigestible matter bigger than the cut-off size of the pylorus, e.g. a large dosage form, will 
be retained throughout the postprandial period. If a large dosage form is given to a patient 
who is in the fasting state then the gastric retention time is dependent upon the onset of the 
next IMMC, which could theoretically be anything from 1 minute to 2 hours later as 
discussed earlier. Kaus et al proved the importance of food, when they administered 
perspex capsules to fasted patients (1984a). The time the capsules took to empty from the 
stomach was erratic, due to the variation in onset of the IMMC, therefore the size and the 
shape of a dosage form makes no difference to the gastric residence time if the stomach is 
in the fasted state. It has also been shown that the presence of food in the stomach slows 
the emptying rate of multiparticulate systems (O’Reilly et al, 1987).
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It has been shown that the composition of the meal is also important in relation to 
the absorption of theophylline from a controlled release single unit dosage form (Karim et 
al, 1985), which is probably indicative of an altered gastric residence time. Davis et al 
found that an osmotic device, of 7 mm diameter, was retained in the stomach for over 10 
hours after ingestion of a high calorie breakfast, whilst the same dosage form was retained 
for a much shorter duration after a low calorie breakfast (1984).
The size of a dosage form will have an effect on gastric residence time when food 
has been consumed. There is always the possibility that the formulation will empty due to 
chance, along with any digested food, if it has a diameter smaller than the pyloric cut-off 
size. This cut-off size was thought to be 2mm, which had been extrapolated from dog 
studies (Khosla and Davis, 1990). However, more recent studies have shown that the 
critical size could be as high as 12mm, although it is more likely a graduated scale 
(Timmermans and Moes, 1993). Attention must be paid if designing such a dosage form 
because there is a risk of causing gastric obstruction if a nondisintegrating formulation, 
bigger than the resting pyloric diameter, is swallowed (Khosla and Davis, 1990).
However, studies so far have only taken the initial size of the formulation into 
consideration when discussing the effect of size on gastric retention. It may be more 
relevant to measure the robustness of a formulation, as it is possible that a large ‘fluffy’ 
tablet may be able to pass through the pylorus if it has a relatively small robust centre.
This may be the case in formulations that consist mainly of hydrogels such as 
hydroxypropylmethylcellulose (HPMC).
1.4 Controlling the gastrointestinal transit of dosage forms
Numerous approaches have been developed recently in an attempt to control the 
transport of dosage forms through the GI tract, with special attention being given to 
prolonging the residence time in the stomach. Retention of a drug delivery system in the 
stomach is one way of improving and controlling the absorption of drugs with an 
absorption window in the upper small intestine, by releasing the drug at a controlled rate 
over the main absorption site for a prolonged period. Topical drug delivery to the gastric 
mucosa, for example, antibiotic administration for Helicobacter pylori eradication in the 
treatment of peptic ulcer disease, would also be facilitated (Yang et al, 1999).
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The methods used thus far to delay gastric emptying can be divided into three sub­
sections; physical, physiological and pharmacological.
1.4.1 Physical methods of delaying gastric emptying
Physical methods that formulators have tried to utilise include floating systems, 
bioadhesive systems, rapidly swelling systems, high-density pellets and a shape system.
1.4.1.1 Floating systems
Floating systems have attracted attention from scientists interested in increasing the 
gastric retention time of controlled release devices, and indeed there has been some success 
achieved in this field since the earliest description in 1975 (Sheth and Tossounian).
Various formulations have been considered including, capsules (Timmermans et al, 1989; 
Cook et al, 1990; Oth et al, 1992; Timmermans and Moes, 1994; Menon et al, 1994; Mazer 
et al, 1998), tablets (Ingani et al, 1987; Hilton and Deasy, 1992; Desai and Bolton, 1993; 
Yang and Fassihi, 1996), and multiparticulate or granular systems (Ichikawa et al, 1991; 
Thanoo et al, 1993; Yuasa et al, 1996; Iannuccelli et al, 1998a and b; Whitehead et al, 
1999). The systems can be classified, in terms of behaviour, into either monolithic (tablets 
and capsules) or multiparticulate dosage forms, both of which aim to remain buoyant on 
the gastric contents, which have a density of approximately 1.004g/cm3 (Lentner, 1981), 
without affecting the intrinsic rate of gastric emptying. It follows that in order for the 
floating dosage form to be effective, it must be taken when there is a medium to float upon 
in the stomach. Many studies have indeed demonstrated the failure of floating dosage 
forms to remain in the stomach under fasting conditions. For instance, Sugito et al (1990) 
showed that tablets with a density of 0.86 remained in the stomach for longer than tablets 
with a density of 1.33, when taken after a light breakfast. However, when the same dosage 
forms were taken under fasted conditions no difference between gastric residence times 
was detected. A small problem with this study was the different size of the dosage forms 
used, as the diameter of the tablets could have had an effect on the gastric emptying. The 
reason for the failures is the so-called housekeeper wave of the IMMC that was mentioned 
previously. Such a limitation must therefore be taken into account when considering the 
use of floating dosage forms. However, providing that the formulation is capable of 
remaining buoyant and a gastric medium is available, then the digestive state of the subject
becomes the rate-limiting step. The floating dosage form is in effect, due to its distance 
from the pylorus, protected from a random, early and erratic emptying during the digestive 
phase, even if the size of the dosage form is smaller than diameter of the pyloric opening 
(Timmermans et al, 1989).
A number of investigations, however, have come to the conclusion that the density 
of a dosage form does not significantly influence its gastric residence time (Davis et al, 
1986d; Kaus, 1987). Davis and co-workers (1986d) did not detect any gastric residence 
time differences relating to density when comparing either floating capsules or tablets with 
non-floating tablets, in a study using gamma scintigraphy. They found that food was the 
major factor controlling the gastric emptying of both dosage forms. However it has been 
confirmed since, in an in vitro experiment (Timmermans and Moes, 1990c), that the 
floating forms used in the experiment produced quite unsteady and inappropriate floating 
characteristics and often sank after a few hours. It could be possible that the units float in 
vivo, but even still the study is significantly flawed due to the size difference (6.9mm for 
the floating capsule to 10.0mm for the non-floating tablet) in the dosage forms chosen for 
the study. We can therefore draw no conclusions about buoyancy / density, from the study.
Kaus agreed with the conclusion made by Davis in a published letter (1987), the 
focus of the letter was based on a previous article that showed no difference in the gastric 
residence times of two indigestible Perspex units (Kaus et al, 1984a), with gravities of 1.03 
and 1.61mg/mm3. As the capsules are made of Perspex, it therefore follows that their 
densities cannot change with time, and as neither of the capsules have a density 
significantly less than that of the gastric fluids, we cannot expect either of them to float 
with any degree of certainty. However, the study was actually carried out in the fasting 
state, which as discussed earlier, is not an appropriate time to administer floating dosage 
forms due to the IMMC.
The size of the dosage forms can be a critical factor when comparing the gastric 
residence times of formulations. It has been proven that as the dosage form becomes 
bigger (4.8-7.5-9.9mm), the gastric residence time for both floating and non-floating 
formulations becomes longer (Timmermans et al, 1989). It has also been shown, in the 
same publication, that the difference in gastric retention time, between floating and non­
floating devices, is more pronounced at the smaller and medium sizes. The data from this 
experiment was taken after the patients had consumed a small breakfast prior to 
administering the dosage form, with no more food being taken until the end of the trial. It 
proves the theory that the floating of the dosage form avoids the random emptying seen
with the non-floating formulations out of the pylorus along with portions of digested 
matter. It is consequently emptied at the end of the digestive cycle by the housekeeper 
wave. The reason that size retards emptying is that a bigger object is less likely to be 
emptied randomly through the pyloric sphincter. The gastric residence time for large 
floating capsules (9.9mm) was not statistically different from identically sized non-floating 
capsules. This is because once a certain size is reached, the dosage form will not be 
emptied until the IMMC, thus nullifying any advantage induced by floating.
Multiparticulate systems were initially developed in order to overcome the ‘all or 
nothing’ gastric emptying seen with some monolithic dosage forms (i.e. if the 
tablet/capsule gets ejected from the stomach randomly, no more drug is absorbed, therefore 
the patient is under-dosed). They also provide less chance of damage to the gastric mucosa 
which can be associated with some drugs. Floating multiparticulate systems do show an 
increased gastric residence time when compared to non-floating equivalents (Whitehead et 
al, 1999). This correlates with the thoughts of Timmermans et al (1989).
1.4.1.2 Bioadhesive systems
As an alternative approach to increasing the gastric residence time of dosage forms, 
mucoadhesive substances that adhere to the gastric mucosa have been proposed. The 
potential of bioadhesive polymers has been widely discussed in the literature (Park and 
Robinson, 1984; Ch’ng et al, 1985; Longer et al, 1985; Duchene et al, 1988; Harris et al, 
1989; Li et al, 1993), however a lot of the work has focused on the development of suitable 
in vitro techniques and theoretical assessments of the structural requirements needed for 
bioadhesion. Many successful materials have indeed been found during in vitro tests, 
resulting in some detailed structural hypothesis of chemical groups that aid mucoadhesion 
(Tobyn et al, 1996). Some materials that show promise include sodium 
carboxymethylcellulose, sodium alginate and polyacrylic acid. One of the problems 
associated with the use of bioadhesive systems for stomach retention devices is that they 
rely on attachment to mucin on the gastric mucosa. The turnover of mucin in the human 
stomach is, however, quite rapid, which would make it very difficult to adhere a controlled 
release gastric mucoadhesive formulation to the stomach wall for any significant period of 
time (Gupta et al, 1990). We should also consider that, due to the intimate contact 
required, some drugs have the potential to exhibit an adverse effect on the mucosa itself. 
The future for gastric mucoadhesive formulations may lie in the co-formulation of
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bioadhesive and floating properties into a system (Matharu and Sanghavi, 1992, Rosa 
Jimenez-Castellanos et al, 1994, Chueh et al, 1995) but much work still remains to be 
done.
1.4.1.3 Other systems
Other physical methods used to increase the gastric residence time include the use 
of high density pellet systems which may reside in the lower part of the antrum (Bechgaard 
and Ladefoged, 1978) and the use of rapidly swelling systems that are retained due to their 
size, before degrading (Agyilirah et al, 1991; Deshpande et al, 1997). The use of different 
shaped units has also been investigated in dog studies (Cargill et al, 1988). However, the 
use of large irregular shaped units in human volunteers may prove to be dangerous, due to 
the risk of permanent pyloric obstruction. Ion exchange resins have also been attempted 
(Thairs et al 1998) but the turnover of the gastric mucosa may limit the maximum gastric 
residence time.
1.4.2 Physiological methods of delaying gastric emptying
The delaying of gastric emptying using a physiological mechanism requires the 
incorporation of a material into the dosage form that is known to stimulate the duodenal 
receptors responsible for the regulation of gastric emptying. This has been attempted in an 
in vivo study (Groning and Heun, 1984), which incorporated myristic acid, as the 
triethanolamine salt for increased solubility, into the dosage form. The study highlighted a 
major problem with this technique, as the responses seen in the experiment varied greatly 
from individual to individual, depending on the effect of the myristic acid on each 
individual’s receptors. This would therefore lead to variable results on potential patients, 
which would not be acceptable to clinicians.
1.4.3 Pharmacological methods of delaying gastric emptying
This method involves adding a stomach motility reducing agent, such as 
propantheline, into the dosage form (Watanabe et al, 1976). This may prolong the gastric 
residence time as a result of reducing gastric motility. However, this is not really a viable 
option for use in many patients, due to the intrinsic interference with the natural workings
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of the stomach, which would affect absorption and digestion of foodstuffs, as well as 
introducing the possibility of systemic side effects.
1.5 Aims and objectives
Floating systems appear to be the most promising of all the methods utilised so far 
to increase the gastric retention time of dosage forms. The dosage form of choice appears 
to be a gas powered device which has the ability to remain buoyant on the stomach 
contents for the duration of drug release. A powered device would offer extra insurance 
against sinking in vivo, which would minimise the incidence of random emptying that has 
been seen with some of the previous inactive floating formulations (Davis et al, 1986d; 
Kaus et al, 1984a). There is therefore a need for a rationalised approach to gas powered, 
floating dosage form design, which can be achieved using novel, in vitro experimental 
design. This would enable us to evolve a proper mechanistic understanding of the 
behaviour of gas powered, floating dosage forms, which have been designed to remain in 
the stomach for long, reproducible, periods of time.
Such dosage forms do not have current pharmacopoeial testing methods associated 
with them, hence it is important that methods are designed which accurately assess the 
pertinent properties of gas powered floating dosage forms.
Floating dosage forms, in particular, have been shown to have a low degree of in 
vitro -  in vivo correlation. The aim of this study was therefore to design and utilise several 
in vitro techniques capable of assessing, and optimising, the important characteristics of 
gas-powered floating dosage forms, which in turn would lead to in vivo success.
It was considered particularly important to develop apparatus capable of 
quantifying dosage form buoyancy, gas release rate and the degree of polymer swelling 
within a formulation. These parameters will be discussed in parallel to assess the effect 






This chapter will discuss the routine methods used to evaluate the physical 
characteristics of the pharmaceutical solids used in this study. Further chapters will then 
be used to describe, in detail, the novel in vitro methods that apply specifically to floating 
dosage form characterisation. All materials used during the course of the study are listed 
in Table 1, Section 2.2., Page 13.
Physical characterisation of pharmaceutical solids can be conducted at three 
primary levels; the molecular level (properties associated with individual molecules), the 
particulate level (properties pertaining to individual solid particles) and the bulk level 
(properties associated with an assembly of particles) (Brittain et al, 1991). This chapter is 
concerned essentially with the bulk physical properties of dosage forms.
Bulk physical properties can be defined in terms of material structure, porosity, 
pore size distribution and surface area. Tablet properties, such as hardness and weight 
variation, are well-recognised parameters used within the pharmaceutical industry.
Specific surface areas can be measured using gas adsorption techniques, which depend on 
the ability to predict the number of adsorbate molecules required to exactly cover the 
surface of a material with a single layer of inert gas (Brittain et al, 1991). Accuracy of the 
technique is highly dependent on material properties and experimental parameters.
Quantitative estimates of pore volume, pore diameter and pore area can be obtained 
using the technique of mercury porosimetry. This is based on capillary rise phenomena 
whereby a pressure is required to make a non-wetting liquid move up narrow capillaries 
(Ganderton and Selkirk, 1969). Quantitative data is obtained by relating pressure applied, 
and volume of mercury intruded, to pore size distribution, pore volume and pore surface 
area. Mercury porosimetry has gained popularity as a research tool due to the simplicity of 
the technique and the wide range of data that can be generated (Dees and Polderman,
1981). Due to its ease of use, mercury porosimetry is often used as a black box, which 
produces pore size distributions (Van Brakel et al, 1981). However, basic limitations of 
the technique exist and problems may arise if it is applied to materials for which it has not 
been properly tested. To ensure the data obtained is truly representative of the porous 
material; potential sources of error need to be thoroughly evaluated and care must be taken 
with interpretation of results.
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In this study, floating dosage forms were analysed using mercury porosimetry and 
gas adsorption techniques. The objective was to determine the suitability of these 
methods, alone and in combination, for characterising specific surface area, bulk density, 
porosity, pore area and pore size distribution of floating dosage forms.
To achieve this it was necessary to; (1) ensure that the techniques gave information 
which was truly representative of the porous body; (2) assess whether the measurements 
obtained would be potentially useful for physical properties / in vitro behaviour correlation 
studies.
2.2 Materials
Table 1. Materials that have been used during the course of the study
Material Manufacturer Batch Number
Ciprofloxacin Ranbaxy -
Sodium Bicarbonate BDH K25190714839
Xanthan Gum Monsanto 64165V
Sodium Alginate Monsanto 59346A
X-linked PVP BASF 379138
Magnesium Stearate BDH 30120362
Talc Degussa 0891
Carvedilol Cadila Healthcare 9CD003
Dried Glucose syrup Roquette 655310




Ammonium Bicarbonate BDH K25366774844
Lubritab Mendell 666812603X
Emcocel 90M Mendell E9B8A01X
Mercury Belgrave Mercury Ltd -
Tween 20 Aldrich -
Silicone oil Aldrich -
Sodium Chloride Aldrich 4041440408011




Pore size determinations were made using a Micromeritics Autopore II porosimeter 
(Type 9220, Micromeritics Instruments Co., Georgia, USA) capable of operating in the 
range of 3.4 to 414,000kNm‘2. The porosimeter was equipped with a low-pressure chamber 
operating from atmospheric pressure (172kNm‘2) down to 3.4kNm'2 and a high-pressure 
chamber operating from 172 up to 414,000kNm*2. The pressure at which mercury could be 
introduced into the penetrometer (fill pressure) could be controlled between 3.4 and 
69kNm'2. Assuming the contact angle of the mercury to be 130° and the surface tension of 
mercury to be 485.0gcm/s2 respectively, pores having median diameters in the range 360 to 
0.003(xm could be analysed. A hydraulic pump generated pressure and the movement of 
mercury in the penetrometer stem was followed using a conductance detector.
Tablets were tested one at a time in a solid penetrometer that had a stem volume of 
1.131ml. One tablet was used in each test and the test was run in duplicate to assess 
reproducibility. Samples were evacuated down to a pressure of 50|xmHg to remove 
adsorbed gases and moisture. The penetrometer, fill pressure and sample size were 
carefully selected to ensure that between 10 and 90% of the stem volume was used in each 
run. Measurements were carried out at a consistent room temperature of 21°C using an 
equilibration time of 5s. The surface tension, contact angle and density of mercury at 21°C 
were taken to be 485.0gcm/s2, 130° and 13.5g/ml respectively. Between 30 to 50 points in 
the required range were taken.
2.3.2 Surface area analysis by nitrogen adsorption
Nitrogen adsorption onto the surface of tablets was measured using a surface area 
analyser (ASAP 2010, Micromeretics Instruments Co., Georgia, USA). Ideally the surface 
area being measured should be in the region of 20m2. However, since the surface area of 
the tablets was expected to be low (in common with many pharmaceutical products), it was 
decided that three tablets should be used for each analysis in order to increase the available
14
surface area for measurement. To accommodate three tablets, a glass sample tube with a 
volume of approximately 30cm3 was used. Outgassing the samples was necessary before 
testing to remove physio-adsorbed gases and vapours, which can alter surface potential and 
block or fill pores. Vacuum pumping down to a pressure of 8mmHg outgased the samples. 
The samples were outgased directly on the analysis port; thus negating the need for port 
transfer after outgassing so that no atmospheric gas was able to enter the tube. After 
outgassing, the sample was cooled to the boiling point of nitrogen (77K) by immersing the 
sample holder into a dewar filled with liquid nitrogen. The sample was exposed to 
increasing partial pressures of nitrogen and the volume of gas adsorbed was measured at 
each partial pressure.
2.3.3 Measurement of Bulk density
Bulk density was calculated from mercury porosimetry results.
2.3.4 Measurement of Tablet Strength
The crushing strength of tablets were determined using a Schleuniger 2E tensile 
tester (Dr. K. Schleuniger & Co., Switzerland). Ten tablets were tested in order to assess 
reproducibility. Tablets were crushed along the longest face. Measuring tablet strength is 
an established technique to ensure that a batch of tablets has been manufactured within 
recommended limits.
2.3.5 Measurement of Tablet Weight
The weight of tablets was measured using an A and D HM120 balance (Oxford, 
UK). Ten tablets from each batch were assessed in order to determine the reproducibility 
of the tableting process.
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CHAPTER 3




The rational design of in vitro experiments is essential for the thorough 
understanding of any dosage form. Indeed, a large number of physical and / or chemical 
properties exhibited by pharmaceutical products can be measured. It is perhaps even more 
important when we are considering the various intrinsic factors that influence the ability of 
a formulation to float. Floating dosage forms do not have current pharmacopoeial testing 
methods associated with them, hence it is important that methods are designed which can 
assess the integral properties of such dosage forms.
The most important factor to consider when designing floating dosage forms is 
obviously the ability of a formulation to float upon the gastric fluids.
3.2 Background
Until recently, the main parameters that had been used to describe the adequacy of 
dosage form buoyancy were bulk density and, in some experiments, the duration of 
floating. It is, however, not enough to say whether a dosage form floats or not, as it is 
much more preferable to quantitate the force with which the formulation is floating. It is 
also vital to assess the buoyancy profile of the dosage form over a functional time period, 
rather than taking a singular pre-testing density measurement. A common misjudgement is 
that delivery systems travel in an uncontrollable way through the length of the 
gastrointestinal tract. This has in turn led to a lack of correlation between in vitro /  in vivo 
results. For instance, Davis has shown the absence of correlation between the cumulative 
data of in vitro release and in vivo absorption for a drug given to fasted patients in the form 
of a monolithic osmotic tablet (1986c). Many other investigations in humans have also led 
to conflicting conclusions when using floating dosage systems. Studies have shown 
systems thought to float in vitro that did not provide a significantly prolonged gastric 
retention time when compared with non-floating systems in vivo (Bechgaard and 
Ladefoged, 1978; Davis et al, 1986d; Kaus, 1987; Sangekar et al, 1987).
According to the known properties of fluids (Cromer, 1981), it is possible to note 
that although density may express whether an object will float, it does not represent the
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magnitude of the floating forces produced by the object. In addition to this, a single 
density determination that is made prior to immersion does not enable one to foresee the 
floating force evolution of a dosage form, as the dry material of which it is made 
progressively reacts or interacts with the medium surrounding it.
These problems have recently been overcome with the invention of a piece of 
equipment that is capable of measuring the buoyancy force of a dosage form over a period 
of time (Timmermans and Moes, 1990a and b). A schematic of the apparatus is shown 
below in Figure 1 (page 19). The equipment consists of an electronic toploader balance 
<1> and a force transmitter device <6,7,8> (FTD) that extends vertically down from the 
measuring module of the balance into the opening of a test container <12>. Rigid 
connection between the upper end of the FTD and the junction point of the electromagnetic 
measuring module is ensured in such a way that all vertical upward or downward 
displacements of the FTD are perceived by the measuring module and displayed by the 
balance. The lower end of the FTD holds a test sample totally submerged in the test 
solvent at a constant immersion depth. The test solvent is maintained at a constant 
temperature, in an environment free from vibrations, by a water bath <13>. A draft 
protection assembly covers the pan of the balance <2>. The data is collected and plotted 
by a paper chart recorder <29>. A liquid compensating system is in place as an attempt to 
counteract the effects of evaporation from the test container <17-24>.
This apparatus makes it possible to determine the force with which a dosage form 
floats over a period of time. It then becomes possible to optimise the floating capabilities 
of a formulation before commencing in vivo testing. The apparatus has been used to assess 
some of the previous work carried out on floating dosage forms (Timmermans and Moes, 
1990c).
Using apparatus of this kind would make it possible to determine the robustness of 
a particular floating dosage form, and also to gain an indication of what to expect when 
looking for correlation between in vivo and in vitro results. The kinetics of dissolution, 
floating, swelling or disintegration can be determined from use of such an apparatus. The 
measuring process also operates in a non-destructive manner, allowing the real behaviour 
of the dosage form to be examined. The profiles produced may in turn be analysed to 
establish the important characteristics and properties of tested materials.
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Figure 1 Schematic of a previous buoyancy apparatus (Timmermans and Moes, 
1990c)
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3.3 Original Apparatus Design
The equipment described above was used as a starting point for the design of an 
apparatus that could be used, in the laboratory, for the detailed assessment of dosage form 
buoyancy over a predetermined period of time. See Figure 2, page 20, for a schematic of 
the new apparatus and Figure 3, page 21, for a digital photograph.
The new apparatus consisted of four main sections, which can be categorised as follows:
1. Balance assembly. An A&D HM120 balance (Oxford, UK) was mounted on a raised 
pedestal to enable it to sit directly above the test medium. The A&D HM120 balance 
was chosen because it has a connection point to the underneath of the balance enabling 
direct access for the FTD connection.
2. Force transmitter device. The force transmitter device is shown enlarged in Figure 4, 
page 22, it is also photographed in Figure 5, page 23. It consists of a PTFE / stainless 
steel shaft, which ends in a basket device for tablet capture. PTFE was chosen as the
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material for the upper part of the device so as to prevent magnetisation of the 
electromagnetic measuring module on the balance. Stainless steel was used for the 
remainder of the shaft so as to limit interaction with the test medium being used, and 
also to provide rigidity to the device. A waist was built into the main shaft at the point 
where the device would be in contact with the surface of the test medium, in order to 
limit the effect of evaporation during the test period. The basket itself was made from 
a stainless steel mesh and was moulded into a half cylinder that would contain the 
floating dosage forms. A meshwork structure was chosen so as to limit the interaction 
that occurs between the sample and the holder. A meshwork holder also allows the 
medium access to the majority of the dosage form, thus helping to limit spurious 
readings.
3. Test Medium. The medium is contained in a modified dissolution vessel capable of 
holding quantities of up to 1 Litre. The medium was covered during heating in order to 
prevent evaporation.
4. Circulating water bath. A Grant Y6 (Royston, UK) water bath was used. The water is 
circulated and heated, so as to enable temperature maintenance and control.
Figure 2 A schematic of the initial buoyancy device
20
Figure 3 A picture of the buoyancy apparatus
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Figure 5 A photograph of the FTD and water bath assembly
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3.4 Initial Method
lOOOmls of Millipore water, measured in a volumetric flask, were placed into the 
modified dissolution vessel and heated to 37.0°C. The heating process took approximately
1.5 hours, and was conducted whilst the vessel was covered with a modified dissolution 
vessel top. The FTD was connected to the balance and the unit was lowered into the 
dissolution vessel so that the meniscus of the water was level with the mid-point on the 
waist of the FTD. The balance was then zeroed and readings from the balance were taken 
at intervals of 1 hour over a 4-hour period. The run was repeated 4 times to assess 
reproducibility.
3.5 Initial Modifications to Original Design
The results (see Figure 6, page 25) that were seen from the 4 runs were too erratic 
for the method to be considered reproducible enough to be used to compare floating tablets 
in future work. The graphs all showed an increase in resultant weight, which was due to 
the loss of water from the system. The variations in the results were thought to be mainly 
due to 2 factors:
1. The temperature in the laboratory varied noticeably from day to day. This would 
certainly have had an effect on the evaporation of the water from the dissolution vessel 
during the course of the experiment. In order to minimise the variation that was seen, it 
was decided to move the vessel to a laboratory where the temperature of the air could 
be controlled.
2. The waist that had been designed into the FTD, to minimise the effect of evaporation 
on the change in balance weight, was having a detrimental effect on reproducibility. 
This was due to the level of the water dropping more than had been expected over the 
course of the experiment. As the water level approached the bottom of the waist, it was 
thought that the surface tension of the water ‘attracted’ the FTD to the surface, and 
therefore a change in the gradient of the buoyancy graph was seen, adding to the 






















0 1 2 4
Tim e (h o u rs)
Another problem the experiments highlighted was that taking 4 or 5 data points 
over a 4-hour period was insufficient to accurately assess the buoyancy profile. For 
example, the exact time point at which the waist was affected by the surface tension of the 
water was impossible to deduce. This problem can be overcome by linking the vessel to a 
computer capable of constantly logging data points at a predetermined rate. The overall 
graph would then show exactly what was happening at any particular time point, enabling 
a better understanding of the mechanisms that are involved, rather than the ambiguous 
picture currently being portrayed.
Software called Collect (A&D, Oxford, UK) was installed onto a personal 
computer, which was in turn connected to the balance by an RS232 interface cable. The 
RS232 interface is used to convert the digital readings of the balance to an analogue output 
that the computer can recognise. The settings on the Collect program can then be adjusted 
to the users specification for any particular run, and the data readout can be collected from 
the balance at predetermined time points directly into a compatible spreadsheet package.
A further alteration to the design of the apparatus was the addition of a piece of 
mesh to the bottom of the FTD in order to render it capable of holding a tablet before 
immersion. This alteration was made before any further work was continued.
In order to minimise the effect that any dissolved gases may have had on buoyancy, 
it was decided that any fluid used in future experiments should be degassed with Helium 
for approximately 1 hour.
3.6 Secondary Method and Results
The improvements from the previous experiment were all put into place before the 
work continued. A second run using the revised apparatus was conducted according to the 
following revised methodology:
lOOOmls of Millipore water were measured out into a volumetric flask. Helium 
was then bubbled through the water for 1 hour, to remove dissolved gases. The degassed 
water was transferred to the modified dissolution vessel and heated to 37.0°C, which took 
approximately 1.5 hours. During heating the vessel was covered with a plastic top to keep 
evaporation to a minimum. The temperature of the water was checked using a mercury
26
thermometer before the experiment was started, to ensure the medium had been stabilised 
at 37°C.
The FTD was then connected to the balance and the unit was lowered into the 
dissolution vessel. The balance was zeroed and the reading from the balance was taken at 
intervals of 60 seconds, using the Collect software, over a period of 8 hours.
The experiments were conducted in a room where the temperature of the air was 
controlled at 20°C. The run was repeated five times in order to assess the reproducibility 
of the technique. The results can be found in Figure 7, on page 28.
The graphs that were produced showed two distinct phases. The first phase 
occurred during the first hour of the test, and was characterised by an apparent increase in 
the weight of the FTD. It is thought that this increase was due to the heating up of the 
probe, combined with water loss through evaporation. As the probe heats up it will 
undergo an amount of expansion, thereby changing the density of the probe. As part of the 
probe is situated in the medium during the test, any change in density will affect the force 
that is being measured by the balance. The second phase continued from the first hour, 
until the end of the 8-hour test period, during which the gradient remained almost constant. 
It is therefore thought that the second phase is purely the result of water loss through 
evaporation, resulting in less of the probe being submerged in the water.
The 5 runs were grouped more closely together than in the previous experiment, but 
were still not deemed suitable as a baseline for future experiments as the resultant weight 
gain on the probe was still too high. It was decided therefore to try and reduce the amount 
of evaporation of water from the vessel so that the overall change in weight could be 
reduced.
It was thought that there was a degree of unpredictability about the graphs being 
produced. It is possible that this was due to condensation of the evaporated water onto the 
FTD that would then slowly aggregate before dripping back into the test medium.
Limiting the degree of evaporation from the medium would also help to solve this 
problem.
Again, there were seen to be sudden forces of attraction caused by the waist in the 
FTD being drawn towards the surface of the liquid in the vessel by the surface tension. In 
order to solve this problem the waist was filled in using a piece of PTFE with the same 
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3.7 Further Modifications to Method
In order to reduce the evaporation of water from the vessel during testing it was 
decided to try to place a layer of oil on top of the water. The theory behind this was that 
the oil would then form a barrier on top of the vessel through which the water would not 
evaporate. Silicone oil was used as the test agent for this experiment as this was readily 
available in the laboratory.
A drop of the oil was placed onto the surface of the water. However, the oil simply 
formed a discreet blob on the surface of the water, which clearly would not be capable of 
limiting the water evaporation as desired. It was decided therefore to mix some of the 
silicon oil with a few drops of Tween 20 before addition to the water. This mixture was 
shaken thoroughly before placing one drop onto the surface of the water.
As expected, the Tween 20 helped the partitioning of the oil and the mixture 
quickly spread itself over the surface of the water. A test run was then performed, as 
before, in order to see if the addition of the oil would hinder evaporation of the water.
The results of this run can be seen in Figure 8, page 30. The weight gain on the 
FTD over the course of the experiment was approximately 2/3 of the previous weight gain 
seen before oil addition. A heating up phase of the FTD was also still being seen, so it was 
decided to modify the method by placing the FTD probe into the medium during the 
equilibration of the fluid to 37°C. This would ensure that the FTD would be at the same 
temperature as the medium at the start of the testing period.
Even though using the oil had reduced the evaporation of the water during testing, 
it was decided that there was potential for the oil to interfere with dosage forms during 
future testing. An alternative way of minimising evaporation was to use insulating 
spheres, such as those used to maintain the temperature of water baths, on top of the water. 
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In order to accommodate the spheres into the system, it was first necessary to ensure that 
the spheres did not affect the FTD on its path into the vessel. A piece of hard plastic 
tubing was therefore cut to size to surround the FTD and prevent the spheres from 
knocking the FTD during testing. The tubing was attached to the top of the balance holder 
by a rubber seal so that it could easily be removed / reattached. The test was then 
performed as before, being repeated five times in order to assess reproducibility. The 
results are shown in Figure 9, page 32.
The overall water loss was reduced so that the effective weight gain on the FTD 
was approximately 0.05g over the 8-hour period. This was deemed to be satisfactory for 
the purposes of the buoyancy apparatus, as it was thought the degree of error would be 
minimal compared to the buoyancy / sinking effect which would be seen when a tablet was 
added. The weight gain for each tablet run is shown below in Table 2, page 31. The 
standard deviation of the weight gains for the individual runs was seen to be 0.00371, 
which was deemed to be satisfactory for this type of test.
Table 2 Total weight gain on the FTD over an 8-hour period using Millipore 
water as a medium

































All of the runs to this point had been performed using Millipore water as a medium, 
however when using floating dosage forms the test will need to be performed with 
simulated gastric fluid in order to mimic stomach conditions. The effect of evaporation 
will, however, vary depending on the medium being used at the time. A baseline blank run 
was therefore performed using simulated gastric fluid. The simulated gastric fluid (SGF) 






The following method was used for the pre-testing of the system, as well for all 
future tests using the apparatus:
■ The SGF was produced according to Formula 1 and was then degassed by bubbling 
Helium through the mixture for 1 hour.
■ lOOOmls of SGF were transferred to the modified dissolution vessel. The loose FTD 
was placed in the fluid and the top of the vessel was covered with the modified 
dissolution top. The water bath was then heated to 37°C. The heating up process took
1.5 hours, and the temperature was checked using a mercury thermometer before 
testing began.
■ Once 37°C had been reached, the top was removed from the vessel and the FTD was 
taken out, quickly dried, using paper tissue, and then connected to the balance, with the 
protective shield surrounding the top portion of the FTD.
■ The balance assembly / FTD was then placed back into the fluid and the insulating 
spheres added over the surface of the medium in a monolayer.
■ The balance was tared.
■ The balance was then lifted out of the water bath and held for approximately 3 seconds, 





be added at this point), before being re-submerged. The data collection was then 
started.
■ The run was performed over an 8-hour period, with data being taken every 5 seconds.
The average overall weight gain was 0.04g (see results in Figure 10, page 35), 
which was similar to the results achieved when Millipore water was used. An approximate 
difference of 0.015g was found between the overall weight gains of the 5 runs, with a 
standard deviation of 0.00652, which was deemed appropriate for this study (see Table 3, 
page 34).
Table 3 Total weight gain on the FTD over an 8-hour period using SGF as a 
medium








The apparatus was therefore ready to be used as a comparative test for floating 


























PRESSURE VESSEL DESIGN AND DEVELOPMENT
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4.1 Introduction
The release of gas from a component within a floating dosage form, if controlled 
properly, offers considerable benefits for the formulator. It can enable dosage forms to 
have their own floating power generator and can considerably increase swelling if a 
coating were applied to the outside of a tablet. Obviously, this production of gas has to be 
at a predetermined rate and has to take into account the swelling / gel strength of the 
polymer matrix into which it is embedded. It is therefore of benefit to have an in vitro 
technique capable of measuring the rate and extent of gas release from a tablet system.
4.2 Background
The release of gas from a component within a dosage form is of considerable 
interest in various pharmaceutical systems. The controlled production of gas is capable of 
aiding tablet disintegration, as in effervescent dosage forms, and of conveying buoyancy to 
floating dosage forms (Ingani et al, 1987; Yang et al, 1999). Both these systems would 
benefit from an in vitro technique capable of fully characterising and accurately 
quantifying the rate and extent of gas production by the dosage form, thereby allowing the 
optimisation of a formulation.
According to the ideal gas law (see Equation 3, page 39) an inversely proportional 
relationship exists between volume and pressure in a closed system, assuming the 
temperature in the system remains constant. It is therefore possible to calculate any change 
in the gaseous volume of a closed system, by measuring the pressure change that occurs 
within that system.
Some work has been conducted previously which looked at the production of gas 
after a reaction involving sodium bicarbonate powder (Fordtran et al, 1984). However the 
system used relied on the measurement of a displaced volume of gas after the bicarbonate 
had reacted. This technique is not accurate enough for studies on floating dosage forms as 
the amount of gas produced is envisaged to be relatively small. Also, the experiment only 
yields the total quantity of gas produced by the system, when it is the rate of production 
that is integral to this study.
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A pressure device for measuring gas release from effervescent systems has also 
been attempted previously (Anderson et al, 1982). The experiment consisted of a closed 
plastic vessel containing a test medium, into which the test tablet was dropped at time zero. 
A pressure monitor was attached which measured the rate of pressure change as the gas 
was released from the effervescent system. Unfortunately in this experiment, a vessel 
made from an unspecified plastic had been used. Some plastics may become slightly 
deformed under increased pressures, which would mean that the internal volume of the 
vessel would not remain constant throughout the duration of the experiment, leading to 
potentially erroneous results. The pressure monitor used was also only accurate to 2psi, 
which would not be sufficiently accurate to measure the much smaller change in pressure 
envisaged with a gas powered floating system. However, the main flaw in the experiment 
was that the close relationship between pressure and temperature had been largely ignored. 
The vessel itself was not temperature regulated, which would cause fluctuations in the 
pressure within the vessel as the gas expanded / constricted due to temperature 
fluctuations.
4.3 Original apparatus design
4.3.1 Theory behind apparatus measurements / specifications
A gas powered floating dosage form must have the capability to produce gas at a 
predictable, reproducible rate. It is therefore essential that we have a piece of apparatus 
capable of measuring the rate of gas evolution from a dosage form in vitro.
Currently, the most widely used gaseous system in pharmaceutical effervescent 
formulations is carbon dioxide. Carbon dioxide is normally produced using the reaction 
that occurs between citric acid and sodium bicarbonate, when catalysed by water (see 
Equation 1, page 38).
Equation 1
E.g., Citric acid + 3NaHCC>3 3 H2O + 3CC>2 + Citric residue
Rmm = 192 Rmm = 84
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Therefore, the reaction of 1 mole (192g) of citric acid with 3 moles (252g) of 
sodium bicarbonate yields 3 moles of carbon dioxide. The volume of 1 mole of gas at 
273K is 22.4dm3 (24dm3 at 298K). Therefore the 3 moles of CO2 generated in the reaction 
have a volume of 72dm3 at 298K, assuming the reaction goes to completion.
In a gas powered floating dosage form, it is envisaged that the maximum amount of 
sodium bicarbonate present in the formulation would be somewhere in the region of 60mg. 
Any more sodium bicarbonate than this would begin to cause problems with the size of the 
dosage form that would need to be produced.
The ratio of the components needed to fulfil the reaction shown above are 1.3125g 
sodium bicarbonate : lg  citric acid. Therefore if we use the theoretical maximum of 60mg 
of sodium bicarbonate the above equation becomes:
Equation 2
60mg NaHCC>3 + 46mg Citric acid 0.017 dm3 of CO2 at 298K (17cm3)
We can therefore assume the maximum amount of CO2 that would be produced in a 
gas powered floating dosage form would be in the region of 17cm3.
The ideal gas law is stated in Equation 3:
Equation 3
PV=nRT where: P = Pressure (Pa)
V = Volume (L) 
n = moles of gas X 
R = Gas constant 
T = Temperature (K)
Rearranging the equation enables us to establish a relationship between Pressure 
and Volume: P 1/V, assuming that the temperature remains constant. Therefore in a 
theoretical 100cm3 closed system resting at 1 Bar pressure, a 0.1 cm3 addition of gas will 
result in a pressure rise of lmbar, if the gas behaves ideally. It follows that an addition of 
17cm of CO2 , into the same system, would yield an increase in pressure of 170mbar.
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Based on the work reviewed previously, a rationally designed pressure vessel 
would present a viable system for in vitro measurement of gas release from a floating 
dosage form. The data that has been considered above dictates that the design of any 
pressure vessel should be loosely based on a 100cm gas system, and be attached to a 
pressure transducer capable of measuring between 0 and 170mbar.
4.3.2 Experimental design
As shown in Figure 11, page 41, the pressure vessel consists of a main glass 
assembly that is detachable into two sections, separated by a ground glass joint designed to 
convey an airtight seal. Glass was the medium of choice for the body of the vessel for two 
reasons. Firstly, the glass structure would enable us to see into the vessel during 
experimentation. Secondly, glass is unlikely to swell upon prolonged heating, thus 
ensuring that the internal volume of the vessel remains constant throughout the duration of 
the experiment. Figure 12, page 42 shows a schematic of the vessel. When in use, the 
ground glass joints are covered with a silicone sealant to avoid the possibility of escaping 
gas. The internal volume of the vessel was approximately 200cm , so it is envisaged that 
approximately 100cm3 of airspace will remain once a medium has been added. This 
volume is in keeping with the theory discussed above.
The lower section of the vessel has been designed to contain the sample being 
tested, along with any medium being used. The vessel, containing a stirring flea, sits on a 
Heidolph MR 300 C (Schwabach, Germany) magnetic heated stirrer, set at 100 rpm in 
order to agitate the medium, hence replicating stomach conditions and providing a more 
even dissolution. A water bath surrounds the lower portion of the vessel such that the 
internal medium temperature can be set to 37°C.
The upper section of the vessel has been designed to include both a means of 
monitoring internal pressure, and an inlet / outlet valve for gaseous addition / release. The 
valve itself consists of a modified subaseal piece, which is screwed into place directly onto 
the glass vessel. A Druck PDCR 820 (Leicester, UK) pressure transducer conducts the 
monitoring of the internal pressure. The transducer has a range of 200mbar and an 
accuracy of lmbar pressure, which is in correlation with the theory above. The transducer 
is linked to a digital output device that facilitates the reading of pressure levels at various 
time points.
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Figure 11 Photograph of pressure vessel
4 1
Figure 12 Schematic of pressure vessel design
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4.4 Initial calibration methodology
The calibration method used consisted of the addition of known aliquots of CO2 
into the closed pressure vessel, in order to assess the change in internal pressure. 
Decarbonated water was used as the medium in the vessel, so as to ensure that all CO2 
produced came from the gaseous additions. Decarbonated water also had the advantage of 
being an easily reproducible medium to make.
The decarbonated water was produced by vigorously boiling reverse osmosis water 
for 10 minutes, and then cooling whilst protecting from the atmosphere (British 
Pharmacopoeia, 1993). 90mls of this medium were then measured using a 100ml- 
measuring cylinder, before transferring them to the pressure vessel. The pressure vessel 
was then heated to 37°C on the heated magnetic stirrer, with the stirrer speed set to 
lOOrpm. This process took approximately 90minutes to stabilise, after which time the 
vessel was sealed and the pressure reading zeroed.
4 2
The carbon dioxide itself was produced using cardice. A conical flask was first 
purged with CO2 gas from a compressed cylinder. The cardice was then added to the 
purged flask and the top covered with a subaseal bung, using a needle to vent. A Weber 
scientific BS 1263 5ml-glass syringe, attached to a needle, was then used to collect known 
amounts of pure CO2 gas from the flask. The syringe was allowed to equilibrate to 
atmospheric pressure, before injecting the required amount of CO2 through the inlet valve 
and into the decarbonated water in the pressure vessel. The CO2 was injected directly into 
the medium in order to mimic the effects of gas release from a tablet. The pressure 
readings were taken 5 minutes after the addition of the CO2 , in order to give the system 
time to equilibrate. 1ml of CO2 was added initially followed by 5ml additions until near 










Figure 13 A graph to show the relationship between CO2 addition and pressure in a closed vessel containing CO2 free water
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4.5 Modifications to the original design
Initial results from the experiment (Figure 13, page 44) indicated that pressure was 
being lost from the vessel to some degree. The first modification was to add a firm support 
around the ground glass joint of the pressure vessel to ensure that no gas was leaking from 
this area.
When the experiment was rerun however, it was noticed that the pressure in the 
vessel was dropping rapidly as the needle was inserted past the septum. The experiment 
was therefore terminated. Upon further investigation a leak was eventually located 
through a small aperture in between the needle and the glass syringe. The gap was sealed 
with PTFE tape and the experiment repeated.
During the next rerun of the experiment, gas was found to be leaking from the 
subaseal septum on the inlet / outlet valve. The experiment was therefore terminated 
again. This loss of gas was deemed to be the result of repeated piercing of the septum with 
the syringe needle and highlighted the need for the septum to be replaced before each run.
The corrected experimental calibration was then conducted in triplicate in order to 
assess reproducibility. The experiment was repeated using simulated gastric fluid as the 
medium and also when the pressure vessel was empty, to see the effect that the medium 
has on the pressure levels seen. The simulated gastric fluid was produced according to 
Formula 1, page 33.
4.6 Initial calibration resuits
The calibration proved to be similar for each of the individual conditions, see 
Figure 14, page 47. The slight error seen could have been due to a multitude of factors.
The accuracy of the syringe being used to inject gas introduces a certain error, as does the 
operator. The air temperature while the gas was being measured was not kept constant and 
so will have an effect on the number of moles of gas being injected into the vessel, which 
in turn will directly affect the pressure reading within the vessel. The water bath keeping 
the pressure vessel at 37°C also had a limitation as the temperature fluctuated slightly as
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the heated bath came on. It is perhaps this factor that made the most difference to the 
results.
The overall graphs followed distinctly different patterns, depending on the 
presence, or lack, of fluid in the vessel. When the fluid was present in the vessel, the 
calibration curve could be fitted to a quadratic equation. However, when no fluid was 
present in the vessel a linear calibration was produced.
The predictable curve seen when fluid is used in the vessel is probably due to the 
experimental conditions. The pressure readings were taken 5 minutes after the addition of 
CO2 , and not when the pressure in the vessel had reached equilibrium. When the CO2 is 
first injected into the vessel the pressure reading reaches a peak level before dropping off 
slowly, until finally equilibrium is reached. This is thought to represent the slow 
incorporation of injected CO2 gas into the liquid phase, presumably as carbonic acid. This 
transition causes the pressure in the gas phase of the system to slowly decrease until 
equilibrium is reached. However, as the overall pressure in the vessel increases with each 
further addition of gas, so the rate of CO2 transition increases. This therefore leads to the 
predictable curve seen in the calibration graph.
There is a small difference between the decarbonated water graph and the simulated 
gastric fluid graph, although this difference may not be statistically valid (Figure 14, page 
47). The acidic nature of the gastric fluid could help to explain this perceived difference. 
The acidic gastric fluid would not form carbonic acid as readily as the decarbonated water. 
This would therefore lead to more moles of CO2 remaining in the gaseous phase at 
equilibrium, and hence a higher pressure detected in that phase by the transducer.
The calibration performed without liquid further proves the equilibration theory, 
and validates the fact that no leaks are occurring in the vessel. A linear response was seen, 
as expected, due to the inverse relationship that exists between volume and pressure. We 
can therefore deduce that the curve seen previously was due to the presence of fluid in the 
vessel. The overall pressure levels seen were much lower when compared with the fluid 











Figure 14 A graph to show the relationship between CO2 and pressure in a closed vessel containing different mediums
250














4.7 Secondary modifications to vessel design
The experiments performed on the initial vessel provided useful information 
regarding the relationship between pressure and medium. However, it was decided that 
there were some factors that could be altered to improve the reproducibility of the 
experiments.
Firstly, the temperature of the air / medium inside the vessel cannot have been 
constant throughout the course of the experiment, due the inadequate temperature 
regulation device and the inherent fluctuation in air temperature. Any fluctuation in the 
temperature inside the vessel would have a direct effect on the pressure inside the vessel 
therefore it is essential to try to keep the temperature constant throughout the duration of 
the experiment. It was decided to do this in two ways. Firstly, it was decided to move the 
experiment into a laboratory with regulated air temperature control, so that all experiments 
could be run at the same external air temperature. The second change was to discard the 
previous water bath arrangement that had shown temperature fluctuations during the 
course of the experiment. Such fluctuations were deemed to be a direct cause of the 
majority of the error seen during calibration. It was decided to replace the water bath 
arrangement with a water jacket connected to a circulating water bath (Grant Y6, Royston, 
UK), as this was considered the best way to maintain a constant temperature. Therefore, 
both the internal and external temperatures would now be kept constant for the duration 
and repetition of future experiments, leading to a reduction of overall error.
In order for a glass water jacket to be added it was necessary for the vessel to 
become slightly larger. This was due the difficulty encountered when fitting a glass jacket 
around the existing structure. This obviously led to the requirement for re-calibration of 
the new apparatus, as the internal volume had altered which would inevitably change the 
pressure readings seen when equivalent levels of gas were added.
A second factor thought to have a degree of error associated with it was the speed 
of stirring due to the stirring flea. It was noticed that when the stirring speed was 
increased, the time for equilibration of pressure in the vessel decreased. During the 
calibration experiment there was a delay between gaseous addition and the recording of the 
pressure reading. It was thought that any change in the speed of the stirring flea from day 
to day might well affect the outcome of the experiment. Such a change would have been
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possible, but not easily detected, as the magnetic stirrer used had a non-digital setting 
system. Had the setting been altered in any way, it may not have been possible to return to 
the exact same setting as before, thus invalidating any calibrations. Changing the stirring 
slightly would also effect the dissolution from a dosage form being tested, which would 
also cause problems during later experiments. It was therefore decided that removing the 
flea from the system would the best way of achieving reproducible results over the course 
of an experiment, and to avoid day to day variations.
The third alteration to the system was made to the digital output device. The 
previous device had been calibrated and set up by in the engineering department at the 
University of Bath. However, the main flaw with this set up was that the readings had to 
be taken manually over the experimental period. It would be possible to miss significant 
events when testing a dosage form in the apparatus if an event happened in between data 
points. In order to minimise these errors and problems it was decided to link the pressure 
transducer up to a P.C. via an RS232 interface. The data could then be automatically 
recorded into a compatible spreadsheet package, at various predetermined time points.
This was achieved by using Collect software (A&D instruments, Oxford, UK). In order to 
utilise the RS232 interface it was first necessary for the device to be returned to the 
manufacturer for re-calibration and connection to their own digital readout device. The 
digital device was then connected to the RS232 cable and linked to a compatible P.C..
As the transducer had been re-calibrated and connected to the P.C., it was first 
decided to conduct a blank run with the transducer completely disconnected from the 
pressure vessel. The purpose of this experiment was to see if any fluctuation occurred after 
the pressure transducer was turned on for testing, as it was thought there may be a 
“warming up” effect. The transducer was switched on and the software was set up to 
collect data every 5 seconds over a 4-hour period. The results of this run can be seen in 
Figure 15, page 50.
The graph produced showed that there was indeed a period of “warming up” after 
turning on the transducer. It was decided therefore to leave the transducer on permanently 
between experiments, rather than switching on and off as before.
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4.8 Further modifications to methodology
It was important to establish a reproducible method before any blank runs were 
conducted with the new apparatus, so that all future experiments could follow the same 
protocol. In order to achieve this the method must take into account the addition of a 
dosage form into the apparatus, as this will be an essential part of future work using the 
vessel.
The addition of a dosage form into the vessel can be achieved in two ways. The 
medium in the vessel can be heated before the formulation is added, with the vessel then 
being sealed and the test started. Alternatively, the dosage form can be added prior to 
heating the medium, with the vessel being sealed from the start. Both of these methods 
were investigated without dosage forms, in order to investigate the potential problems or 
advantages that each would bring.
The first to be examined was the heating up of the medium before the theoretical 
dosage form was added into the vessel. In this experiment, SGF was used as the medium
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because SGF will be used in later tests. The SGF was prepared according to Formula 1, 
page 33. 90mls of medium were placed in the vessel and the vessel jacket was connected 
to the circulating water bath, which was set to 37°C. The top was left off the pressure 
vessel during heating. The heating lasted for two hours to ensure that the medium had 
reached 37°C. The temperature of the medium was checked using a mercury thermometer 
prior to the start of the test. The top of the vessel was then sealed and data collection was 
started. Data was collected, using the Collect software, at 5-second intervals for the 
duration of approximately seven hours. The test was repeated in order to assess the 
reproducibility of the technique.
The results are shown in Figure 16, page 51. The graphs both showed an increase 
in pressure at the beginning of the test. This increase was thought to be due to the heating 
of the air above the warm medium once the vessel had been sealed. This heating up phase 
precludes this method from further analysis, as it will distort the graph produced when 
tablets are used in later tests. The pressure in both runs then decreased over the remainder 
of the test. However, the graphs showed a fluctuation of up to 2 mbar between adjacent 
points, rather than the straight line that was predicted. This fluctuation was too high for 
this technique to be used in future runs involving dosage forms.
Figure 16 A graph to show the relationship between pressure and time when the 




The second technique to be examined was the sealing of the vessel before the 
medium was heated. 90mls of SGF were again used as the medium. The vessel was 
heated in the same way as the previous test, only this time the vessel top was on and sealed 
during heating. After 2 hours the vessel was vented using a fine needle to release the 
pressure that heating had caused, and then data collection was initiated in the same way as 
before. The run was again repeated in order to assess reproducibility.
The results are shown in Figure 17, page 52. Both runs showed a general decline 
over time in a similar fashion to the experiment conducted with the top off during the 
heating phase. However, this time there was no corresponding increase at the beginning of 
the test, making this method more viable for future work. This was because the air in the 
vessel had already reached the same temperature as the medium prior to data collection 
being initiated. Both runs however, again showed the approximate 2 mbar fluctuation 
between corresponding points, rather than the expected straight line. This method seemed 
to work well apart from the rapid pressure fluctuation that was being seen in the vessel.
Figure 17 A graph to show the relationship between pressure and time when the 





It was likely that the rapid pressure fluctuations were due to a change in the 
temperature of one of the two phases, within the vessel. The fluctuation can not have been 
due to the temperature of the medium phase changing for two reasons. Firstly, the changes 
in pressure were occurring very rapidly, something highlighted by the taking of data points 
every 5 seconds. It is highly unlikely that the SGF medium could change temperature as 
rapidly as this. Secondly, the temperature of the circulating water bath was seen to remain 
constant during the course of the experiment, meaning the medium was also being kept at a 
constant temperature.
Therefore, it was thought that the pressure fluctuation was due to the temperature of 
the gaseous phase changing rapidly. It is unlikely that the entire gaseous phase can be 
changing temperature, and therefore pressure, over the short time periods indicated. It is 
likely instead, that some sort of temperature cycling was occurring within the gaseous 
phase of the vessel.
The temperature cycling effect was thought to be due to the increased headspace of 
approximately 50mls now present in vessel 2. The heated medium was situated at the 
bottom of this headspace, whilst the pressure transducer measured the pressure at the top.
It was likely that the whole of the headspace was not being equally heated by the medium 
at any one time, and that therefore temperature discrepancies exist between the top and the 
bottom of the headspace. The mechanism for this action can be explained in 4 steps:
1. The liquid medium is heated to 37°C by the water jacket.
2. The gas immediately above the liquid medium is heated to approximately 37°C and 
begins to rise with colder air replacing it.
3. As the warm gas rises it displaces colder gas from the top of the vessel where the 
transducer is monitoring the pressure.
4. The warm gas cools at the top of the vessel and begins to drop, being replaced by gas 
that has been more recently heated.
Steps 2-4 then continue cycling throughout the duration of the experiment. This 
theory would explain the rapid changes in pressure seen in the new vessel. It is the slight 
changes in temperature occurring near to the pressure transducer that accounts for the
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variations in pressure that are measured. This is likely, as there is a close relationship 
between the pressure and temperature of a gas (see Equation 3, page 39).
It is also noticeable that both sets of data show a trend of pressure decreasing 
slightly over time. It is thought that this is due to the slow evaporation of water over the 
course of the experiment. As more water evaporates from the SGF medium, so the volume 
of the gaseous phase increases. If this were taken alone it would explain why the pressure 
in the vessel is seen to slowly decrease over time, due to the inverse relationship that exists 
between the volume and pressure of a gas at constant temperatures (see Equation 3, page 
39). However, the fact that pressure is proportional to the amount of moles of gas present 
in the system also has to be taken into account. Therefore as the water evaporates, so the 
moles of gas in the system increase correspondingly. This leads to an increase in gaseous 
phase volume as discussed, but also to an increase in the moles of gas present in the 
gaseous phase. Neither of these two factors would therefore appear to exclusively explain 
the decrease in pressure over the duration of the experiment, however the system is 
obviously complex.
The pressure drop could be due to the partial pressure of the water contributing to 
an overall decrease in the pressure of the gaseous system. According to Dalton’s law of 
partial pressures, the total pressure of a gas mixture is equal to the sum of the partial 
pressures of the individual gases, providing no chemical reactions take place. Therefore 
the partial pressure of the evaporated water will have a direct effect on the overall pressure 
of the gaseous system. It is perhaps this constant change in the constituents and volume of 
the gaseous system that best explains the pressure drop that is seen in the sealed vessel 
over time.
The main problem that needed addressing was the pressure fluctuation being seen 
in the vessel (Figure 16, page 51 and Figure 17, page 52). As discussed above, it was 
thought that this was due to fluctuations in the temperature of the gas due to a “cycling” 
effect caused by an increased headspace. In order to remedy this, it was decided to 
decrease the available headspace. There are two ways of decreasing the headspace.
Firstly, it would have been possible to build a new vessel. However, it is possible that the 
new model may have also shown the fluctuation effect. Instead it was decided to build an 
insert for the current model, which would occupy part of the headspace in the vessel, 
thereby decreasing the space available for the gas to occupy. As the primary function of 
the insert was to prevent the temperature “cycling” of the gas phase, it was decided the best 
location for the insert would be halfway between the medium and the pressure transducer.
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The insert could then regulate the flow of the warmer / cooler gases as they rise and fall 
within the vessel, thereby stabilising the pressures read by the transducer and creating a 
more even environment.
The insert was made from perspex to avoid the possibility of interaction with either 
the medium or gaseous phases. The perspex was cut so that it fitted snugly into the vessel, 
and a hole was drilled through the middle of the insert to allow gas to pass through. The 
hole was drilled to an approximate diameter of 1cm.
To ensure that the insert was working as predicted, 3 blank runs were performed 
according to the following method:
■ 1 Litre of SGF was made up according to Formula 1, page 33.
■ The SGF was then degassed by bubbling helium through the mixture for 1 hour.
■ 90mls of the degassed SGF were then transferred into the pressure vessel using suitably 
sized pipettes.
■ The vessel was sealed shut, using silicon sealant to ensure the vessel was airtight, and a 
clamp placed around the join to ensure stability. The vessel was then zeroed via the 
needle vent.
■ The circulating water bath was switched on to heat to 37°C and data collection was 
started.
■ Data points were taken every 5 seconds over the course of 7 hours, in order to assess 
stability.
The results from the 3 runs can be seen in Figure 18, page 57. The graphs show 
that the insert worked effectively to prevent the rapid fluctuations in pressure seen in 
previous experiments without the insert. The insert will therefore be used in all future 
experiments.
The graphs also all show a rapid rise in pressure that stabilises after 1.5 hours until 
the end of the run. This indicates that the fluid in the vessel is taking approximately 1.5 
hours to fully heat up, as after this time the temperature, and therefore the pressure, in the 
vessel remain constant. It will therefore be necessary to leave a heating time of 2 hours in 
future experiments to ensure the vessel is stabilised before a formulation is added.
The noticeable difference between the three runs is the pressure at which they stabilise. It 
was thought this was due to the varying heat of the medium when it was transferred into 
the vessel. Obviously if the medium was slightly warmer when it was transferred then the
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pressure in the vessel would be slightly higher before the vessel was zeroed. It then 
follows that the change in pressure from the beginning of heating to equilibrium would be 
less than expected. It is highly probable that the medium was at different temperatures for 
each of the runs as the medium was degassed in a separate laboratory without temperature 
control, and therefore likely to suffer from day to day variation. However, although the 
variation between runs was quite high, it is not of consequence to the methodology, as the 
vessel will be vented again immediately prior to tablet addition in future runs. This will be 
done after 2 hours of heating to ensure the equilibrium phase has been reached in the 
vessel. This second venting prior to tablet addition will mean that all future runs will start 
at 37°C and at atmospheric pressure.
The final vessel will have to be able to assess the gas release from various dosage 
forms; therefore the next alteration to the vessel was the design of a mechanism capable of 
adding a test formulation into the vessel. It was important that the mechanism was 
finalised at this stage and added to the vessel, so that the calibration of the vessel could be 
carried out under final test conditions with all components in place. Having previously 
established that the best method of heating the medium was with the vessel sealed, it was 
necessary to have the dosage form in situ before heating was initiated. This caused a few 
problems, as it is necessary to protect the dosage form from the SGF medium during the 
pre-heating phase. The formulation must also be protected from any vapour that may be 
released during heating of the SGF. The other problem that must be overcome is the 
mechanism of release of the protected dosage form into the medium, once pre-heating has 
been completed.
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Figure 18 A graph to show to relationship between pressure and time during and 
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A glass shelf had already been incorporated into the internal structure of the vessel 
during the early design work. It was therefore necessary to design a structure that could sit 
on this shelf and protect, then release, the formulation being tested. It was decided to use a 
piece of hollow perspex tubing as the base for the structure. 30mm of this were cut and 
one end sealed with a flat, circular piece of perspex. A perspex plug was then made to 
loosely fit into the free end of the hollow tubing. The plug was manufactured so that it 
would fall out of the tubing when the tubing was tilted. The plug was then attached to the 
main structure by a small length of cotton. The length of the cotton was such that it would 
allow the plug to fall from the tubing when tilted, but so that it would also suspend the plug 
before it fell into the medium within the vessel. A small amount of silicone sealant was 
placed around the edges of the plug, so that no vapour from the medium could penetrate, 
and therefore react, with the test formulation housed inside. The structure was tethered 
onto the top of the glass tablet shelf inside the vessel, using a plastic pull-tie.
A blank run was performed to test the new mechanism. During the blank run the 
mechanism was proven to protect a blank tablet from SGF vapour. The vessel was then
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tipped to ensure that the plug fell out of the tubing and the tablet dropped into the vessel. 
As this stage also worked without any problems the vessel was now ready for validation.
4.9 Validation of final apparatus and method
4.9.1 Blank runs using final pressure apparatus
In order to validate the pressure apparatus, it was necessary to perform several 
blank runs so that the reproducibility of the system could be assessed under test conditions. 
It was necessary to perform the runs using the conditions that will be used for future tablet 
runs. The following method was used and repeated a total of five times:
■ 1 Litre of SGF was made up according to Formula 1, page 33.
■ The SGF was degassed by bubbling Helium through the mixture for 1 hour.
■ 90mls of the degassed SGF were then transferred into the pressure vessel using 
appropriately sized glass pipettes.
■ The tablet release mechanism was closed with a small amount of silicon sealant added
around the plug section to prevent moisture entering. The previously described insert
was added to the top of the vessel to prevent temperature cycling.
■ The vessel was sealed shut using silicon sealant to ensure the vessel was airtight and a 
clamp placed around the join to ensure stability. The vessel was then zeroed via the 
needle vent.
■ The circulating water bath was switched on to heat to 37°C and data collection was 
started.
■ After approximately 2 hours the vessel was re-zeroed via the needle vent.
■ Immediately after re-zeroing the vessel was tilted to release the plug from the tablet
release mechanism and simulate tablet release.
■ Data points were taken every 5 seconds over the course of almost 10 hours, in order to 
assess stability.
The results from these five runs are shown graphically in Figure 19, page 60. The 
graphs show that all five runs followed a very similar pattern, as expected. The pressure 
can be seen to rise in the vessel during the SGF heating phase. Once the SGF has reached
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37°C the pressure levels off as equilibrium is attained between the liquid and gaseous 
phases. The pressure then decreases rapidly to zero due to the venting of the vessel after 
approximately 2 hours. After venting the runs all exhibit a gradual decline in pressure until 
the end of the experiment. It was thought this gradual decline was due to the effect that the 
partial pressure of water vapour has upon the overall pressure of the gaseous system. This 
phenomenon has been discussed earlier on page 54.
It is noticeable that the pressure in the vessel is dropping below atmospheric 
pressure during this period, therefore the pressure drop is not simply the vessel leaking.
The 5 runs were similar and therefore future experiments will be conducted using the 
average of these runs as a baseline. Figure 20, page 61 shows an average line of the 5 runs 
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4.9.2 Calibration of final pressure apparatus
The calibration method used consisted of the addition of known aliquots of CO2
into the closed pressure vessel in order to assess the change in internal pressure produced.
The calibration was carried out according to the method outlined below:
■ 1L of SGF medium were made up according to Formula 1, page 33. The medium was 
degassed by bubbling Helium through the fluid for 1 hour.
■ 90mls of the mixture were measured out into the pressure vessel using appropriately 
sized glass pipettes. The pressure vessel was sealed and heated to 37°C, for two hours, 
after which time the pressure reading was zeroed using a venting needle.
■ The aliquots of carbon dioxide were produced using cardice. A conical flask was first 
purged with CO2 gas from a compressed cylinder. The cardice was then added to the 
purged flask and the flask covered with a subaseal, using a needle to vent.
■ A Weber scientific BS 1263 5ml-glass syringe, attached to a needle, was used to collect 
known amounts of pure CO2 gas from the flask. The syringe was allowed to 
equilibrate to atmospheric pressure before injecting the required amount of CO2 
through the inlet valve and into the SGF within the pressure vessel. The CO2 was 
injected directly into the SGF medium in order to mimic the effects of a tablet.
■ The pressure readings were taken 5 minutes after the addition of the CO2 , in order to 
give the system time to equilibrate. 1ml of CO2 was added initially followed by further 
5ml additions until near maximum pressure (200mbar) was reached.
■ The calibration runs were repeated a total of five times to assess reproducibility.
See Figure 21, page 63 for the results of all five runs. The average of the five runs










Figure 21 A graph to show the calibration curves for the pressure vessel containing SGF
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22 A graph to show the average calibration curve for the pressure vessel containing SGF
■ 0.0058x + 5 .2 9 8 4 X  
R2 = 0 .9 9 9 9
20
C 0 2 (mis)
“ Seriesl  
" ^ P o ly .  (S eries l)
The experiment was repeated when the pressure vessel was empty to assess the 
effect that medium had on the pressure levels seen. The results for these runs can be found 
in Figure 23, page 66 and Figure 24, page 67.
The calibrations proved to be reproducible under both sets of conditions. The small 
error determined between runs has been reduced from previous calibration attempts. This 
was due to the new experimental parameters introduced into the protocol. The first of 
these was the moving of the apparatus to a room where temperature can be maintained at 
20°C. This helps to maintain the injected gas at a constant temperature and therefore the 
number of moles of gas being injected into the vessel will be more accurate than before. 
The addition of a water jacket to the vessel has also helped to maintain accuracy by 
keeping the internal temperature of the vessel constant, which adds to the reproducibility of 
the experiment. The small error that is still seen is probably due to the inherent inaccuracy 
of the syringe being used to inject the gas, as well as a degree of operator error.
Overall, the graphs followed distinctly different patterns, depending on the 
presence, or lack, of fluid in the vessel. When the fluid was present in the vessel, the 
calibration curve could be fitted to a quadratic equation. However, when no fluid was 
present in the vessel a linear calibration was produced. This pattern is in keeping with 













;ure 23 A graph to show the calibration curves for the pressure vessel containing no medium
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24 A graph to show the average calibration curve for the pressure vessel containing no medium
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A graph to show the effect that medium presence has on the calibration curve for the pressure vessel
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The predictable curve that is seen when SGF fluid is used in the vessel is due to the 
experimental conditions. The pressure readings were taken 5 minutes after the addition of 
CO2 , not when the pressure in the vessel had reached equilibrium. When the CO2 was first 
injected into the vessel the pressure reading reached a peak level before dropping off 
slowly, until equilibrium is reached. This is thought to represent the slow incorporation of 
injected CO2 gas into the liquid phase, presumably as carbonic acid. This transition causes 
the pressure in the gas phase of the system to slowly decrease until equilibrium is reached. 
However, as the overall pressure in the vessel increases with each further addition of gas, 
so the rate of CO2 transition increases. This therefore leads to the predictable curve that is 
seen in the calibration graph.
The calibration performed without liquid further proves the equilibration theory, 
and validates the fact that no leaks are occurring in the vessel. A linear response was seen 
as expected, due to the inverse relationship that exists between volume and pressure. We 
can therefore deduce that the curve seen previously was due to the presence of fluid in the 
vessel.
The overall pressure levels seen were much lower when compared with the fluid 
filled vessels. This is due to the increase in the gaseous phase volume that occurs when the 
fluid is removed from the vessel.
As the vessel has now been calibrated successfully, it is possible to move onto 
testing dosage forms. The testing of dosage forms will be discussed in future chapters.
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CHAPTER 5




The previous two chapters have discussed the development of apparatus capable of 
accurately measuring parameters intrinsically associated with gas-powered floating dosage 
forms. Thus far, methods have been developed that are capable of measuring the buoyancy 
and/or gas release of a dosage form over a pre-determined time period.
This chapter will discuss the in vitro testing of a particular gas-powered floating 
dosage form using the developed test methods. It will also introduce a test to measure the 
swelling evolution of dosage forms, before attempting to rationalise the resulting profiles 
that are seen. The initial surface area of the tablets will also be studied to assess the effect 
that this has on the buoyancy profile.
It is envisaged that this in vitro array of testing methods will be used to explain the 
buoyancy profiles produced by different dosage forms, thereby allowing the formulator to 
systematically produce a dosage form with optimal floating capability.
5.2 Choice of dosage form
Before testing could begin, it was first necessary to select a suitable gas-powered 
floating dosage form. A formulation that had been previously developed by Ranbaxy Ltd 
(India) was chosen as the initial candidate. This formulation was selected as the 
constituents/parameters of the tablet were already known and could therefore be easily re­
produced in the laboratory (see Table 4, page 72). The tablets selected were known to float 
in vivo for approximately 8 hours, making them an ideal candidate for further 
investigation. The formulation is described in detail in US patent 6261601.
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Table 4 Blend Constituents of initial test formulation











5.3 Manufacture of dosage forms
5.3.1 Initial manufacturing method
It was decided to make a 150g batch of the initial blend so that enough tablets 
would be available for all future tests.
The tablets were prepared according to the following method, which was adapted 
from the original preparation method (US patent 6261601) for use in the laboratory:
■ All excipients, excluding the inter-granular magnesium stearate, were weighed out onto 
a balance (A&D HF1200G, A&D instruments, Oxford, UK) and placed together into a 
glass jar. The jar was shaken by hand to roughly mix the excipients.
■ The mix was then screened through a 44-mesh sieve (Endecotts, London, UK) in order 
to break up any aggregates.
■ The sieved mix was placed into a clean glass jar and blended on a low shear, turbula 
mixer (Glen Creston, Stanmore, UK) for 20 minutes at a rate of 20 rpm. The jar size 
was chosen so that the mixture occupied approximately half of the jar volume, leaving 
plenty of room for mixing.
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■ The blend was then slugged using an F-press (Manesty, Liverpool, UK) equipped with 
20mm tooling. The dye was hand filled and the F-press was manually operated.
■ The slugs were dry-granulated through a lmm-mesh screen (Frewitt, Fribourg, 
Switzerland)
■ The inter-granular magnesium stearate was weighed out and added to the granular 
blend, which was then mixed in a glass jar for a further 10 minutes at 20rpm using the 
same turbula mixer.
■ The blend was tabletted using an F-press equipped with specially made caplet tooling, 
measuring 21.5mm by 10mm. Using an A&D HM120 balance (Oxford, UK), 
approximately 1.446g of blend was weighed out onto a plastic weighing boat and 
transferred to the die. The punches were turned over by hand to compact the tablet.
■ Each tablet was made to a hardness of approximately 18KPa.
The tablets were weighed out individually and the F-press turned over by hand, so 
as to decrease the variability that would be seen between tablets. It was imperative that the 
tablets produced in the batch were as similar as possible at this stage as later tests would be 
looking at trends between batches.
Approximately 50 tablets were made from the original blend, but many tablets also 
capped during manufacture. It was thought that the capping was due to the “sticky” nature 
of the ciprofloxacin.
Problems were also encountered during the initial de-aggregation stage (44-mesh). 
It was not possible to force some of the ciprofloxacin through the fine mesh and therefore 
some of the material was lost from the blend.
The tablets that were produced were tested using an array of in vitro tests to assess 
both their dry and wet parameters.
5 . 4  Results from initial batch
5.4.1 Weight variation
The tablets were assessed according to the method outlined in section 2.3.5, page 
15. Results are shown below in Table 5, page 74.
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Table 5 A table to show the weight variation in batch 1















The tablets had an average weight of 1.4399g and a standard deviation of 0.001742.
Most of the tablet weights were grouped closely together, however one or two 
tablets were some distance from the mean. It was thought that this was due to the sticking 
of the ciprofloxacin onto the punch faces during compaction. It is thought that the batch 
tightness could be improved in future manufacturing runs.
5.4.2 Hardness testing
The tablets were assessed according to the method outlined in section 2.3.4, page
15.
The results are shown below in Table 6, page 75.
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Table 6 A table to show the hardness variation in batch 1








The tablets had an average hardness of 17.2KPa, with a standard deviation of 2.41. 
The high standard deviation of this batch of tablets caused concern. A variation in 
tablet hardness will affect the initial density of the dosage form and therefore the floating 
properties of that dosage form. It is possible that swelling and gas release characteristics 
may also be affected.
The variation that was seen was possibly due to the non-uniformity of the blend. 
The blend manufacture will therefore be altered in future runs.
5.4.3 Buoyancy testing
Three tablets from batch 1 were tested in the buoyancy apparatus to ascertain if a 
distinct difference could be seen between the tablet traces and the baseline results from the 
earlier work in Figure 10, page 35. The tablets were tested using the method outlined 
previously in section 3.8, page 33.
























The buoyancy profiles produced for the three tablet runs were at least an order of 
magnitude different from the buoyancy seen due to water loss. This indicates that the 
apparatus is a suitable indicator of floating force, and that it can be used as a future tool for 
buoyancy comparisons.
The profiles produced all followed a very distinctive pattern over the course of the 
experiment, and although the magnitudes of the forces were not always identical, they 
were relatively close throughout the run.
The graphs show that all the tablets had an initial buoyancy period as soon as they 
were immersed in the medium. It is thought that this initial buoyancy is a combination of 
the polymers within the tablet swelling and gas production. The swelling of the tablet 
causes an increase in the buoyancy effect that is seen. This is due to a corresponding 
decrease in the density of the dosage form, caused by the increase in volume. The 
production of gas will also inevitably add to the buoyancy effect that is initially seen.
Some of the gas that is produced as the bicarbonate reacts with the acid medium will get 
trapped within the polymer network of the tablet, therefore helping the tablet to float.
Following the initial buoyancy period the graphs exhibited a slow decrease in 
buoyancy up until approximately 30 minutes had elapsed. This period probably arises as 
the tablet has now swollen to its full capacity and the gas that had been generated, and 
initially trapped, slowly releases as the polymer matrix relaxes.
A second slower buoyancy increase then becomes apparent in all the traces. This 
increase continues until approximately 3 hours after the start of the experiment. It was 
thought that this second phase of buoyancy was due to erosion of the tablet front, resulting 
in an increase in the surface area to mass ratio within the tablet. Gas is still thought to be 
evolving from the tablet at this time, but it may now be more effectively trapped within the 
polymer network, resulting in a more buoyant system.
After 3 hours until the end of the tests, the buoyancy is seen to decrease. This is 
probably due to a reduction in gas evolution and the release of previously trapped gas from 
the matrix. However, all tablets were buoyant throughout the duration of the test.
At various points of the test all profiles exhibit a “jumping” effect where there is a 
sudden loss of buoyancy. This is thought to be due to bubbles of CO2 escaping from the 
polymer matrix and therefore their contribution to buoyancy is lost. All of the various 
hypotheses can be further investigated using gas release and swelling studies.
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5.4.4 Helium pycnometry and mercury porosimetry
To fully understand floating dosage forms it is vital to have the capability to 
characterise the formulation both before and during testing. Mercury porosimetry can be 
used to assess the pore structure of the dosage form before testing. It is possible that 
changing the pore size / structure within a dosage form may have a direct effect on the 
formulation’s interaction with surrounding mediums, especially during the initial periods 
of wetting and subsequent swelling. It is already known that the degree of swelling will 
have an effect on the density of a dosage form, therefore it follows that variation of the 
pore size / structure may yield similar effects.
A second reading that can be taken during mercury porosimetry is bulk density.
The initial bulk density of a floating dosage form is of importance as it dictates whether or 
not the formulation will float when placed into a medium. The bulk density will then 
change over time as the formulation interacts with the surrounding medium, however this 
change can be measured using the buoyancy apparatus described earlier.
Mercury porosimetry is therefore a powerful technique that can be used to help to 
further understand the mechanisms contributing towards the ability of a formulation to 
float. However, before the technique can be used to measure the tablets, the size and 
volume of the stem to use during the experiments must be decided. In order to do this it is 
necessary to first calculate the true density of the blend using helium pycnometry. The true 
density can then be used to calculate the rough porosity of the tablets, which will then help 
to decide which porosimetry equipment to use for future testing.
5.4.4.1 Helium pycnometry and calculations
Helium pycnometry was used to calculate the true density of the blend. An 
accupyc 1330 (Micromeritics, Norcross, USA) was used, and was set to take 10 density 
readings.
The average density of the blend was determined to be 1.5547 g/cm3. From this 
true density value it is possible to calculate the rough porosity of the tablets. In order to do 
so the volume (1) and weight (2) of those tablets must be known and used to calculate the 
volume of powder in each tablet.
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(1) The volume of the tablets was roughly calculated to be equal to:
21.5mm X 10mm X 8mm 
= 1.72cm3
(2) The weight of the tablets was known to be approximately 1.44g.
The volume of powder actually in each tablet can be determined by calculating:
Volume of powder in the tablet = Mass of tablet / True density of blend
1.44g / 1.5547g/cm3 
= 0.926cm3
The rough porosity of the tablets can then finally be calculated as:
Rough porosity = Bulk volume of tablet - Volume of powder in the tablet
= 1.72cm3 - 0.926cm3
= 0.79cm3
When performing mercury porosimetry, optimum results are achieved when the 
porosity of the tablet is between 25% and 90% of the mercury stem volume. A stem 
volume of 1.131cm3 will be therefore be used in all future experiments with tablets of this 
kind.
5.4.4.2 Mercury porosimetry
Having decided which equipment to use, tablets were tested according to the 
protocol outlined in paragraph 2.3.1, page 14. The tablets were tested in triplicate to assess 
reproducibility on this occasion, as it was believed that some variation in tablet properties 
might have occurred during manufacture. See Table 7, page 80 for results.
79
Table 7 A table to show the mercury porosimetry results for tablets made from 
blend 1
Run 1 Run 2 Run 3 Average
Intrusion volume 
ml/g
0.2163 0.2348 0.2309 0.2273
Median pore 
diameter (vol.) pm
0.1140 0.1239 0.1233 0.1204
Bulk density g/ml 1.1787 1.1730 1.0866 1.1461
Apparent density 
g/ml
1.5820 1.6189 1.4506 1.5505
Porosity % 25.49 27.54 25.09 26.04
The results were seen to be reproducible for the three tablets, despite the inherent 
weight variation present in the tablets. The technique will therefore be useful for future 
batches. The bulk of the pores detected were between 0.1pm and 0.2pm in diameter. It is 
possible that there may be some correlation between the pore size and initial wetting / 
swelling of the tablets. The bulk density of this set of tablets was 1.1461 g/ml, indicating 
that the tablets should sink when placed in the SGF medium, however the tablets interact 
with the medium such that they soon float.
All future blends will also be tested with the complementary technique of nitrogen 
adsorption in order to investigate the pore size distribution further.
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5.5 Changes to blending methodology
Due to the inherent variation in basic tablet parameters seen with the previous 
manufacturing conditions, it was decided to alter the methodology in order to improve 
reproducibility.
The main problem encountered during tablet manufacture was the sticking of the 
blend to the punches and the capping that this produced. It was thought that this was a 
direct consequence of poor mixing of the blend, resulting in an uneven distribution of 
lubricant. In order to remedy this situation it was decided to alter three steps of the 
previous manufacturing method:
1 All magnesium stearate will be screened through a 60-mesh sieve using a sieve
shaker (Octagon digital, Endecotts, London, UK) to deaggregate agglomerates. 
This step should ensure that the lubricant is able to disperse evenly throughout the 
blend once it has been added.
2 Pre-blend will now be initially screened through a 22-mesh sieve, rather than the
44-mesh screen used previously. An automated sieve shaker will again be used for 
this process. Some of the blend had been lost in the previous manufacture as the 
44-mesh screen size had been too small.
3 Tablet punches will be wiped clean after each tablet has been produced, in order to 
limit the chances of tablet capping.
5.6 Formulation,  manufacture and testing of blends
Having assessed the initial blending methodology and made the necessary 
alterations, a second blend, consisting of identical excipients (see Table 4, page 72), was 
made and tested. The methodology for the blending and tableting of this blend is shown 
below:
■ All magnesium stearate was screened through a 60-mesh sieve using a sieve shaker 
(Octagon digital, Endecotts, London, UK) to deaggregate agglomerates.
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■ All excipients, excluding the intra-granular magnesium stearate, were weighed out onto 
a (A&D HF1200G, A&D instruments, Oxford, UK) balance and placed together into a 
glass jar. The jar was shaken by hand to roughly mix the excipients.
■ The mix was then screened through a 22-mesh sieve (Endecotts, London, UK), using a 
sieve shaker, in order to break up any aggregates.
■ The sieved mix was placed into a clean glass jar and blended on a low shear, turbula 
mixer (Glen Creston, Stanmore, UK) for 20 minutes at a rate of 20 rpm. The jar size 
was chosen so that the mixture occupied approximately half of the jar volume, leaving 
adequate space for mixing.
■ The blend was then slugged using an F-press (Manesty, Liverpool, UK) equipped with 
20mm tooling. The dye was hand filled and the F-press was manually operated.
■ The slugs were dry-granulated through a lmm-mesh screen (Frewitt, Fribourg, 
Switzerland)
■ The inter-granular magnesium stearate was weighed out and added to the granular 
blend, which was then mixed in a glass jar for a further 10 minutes at 20rpm using the 
same turbula mixer.
■ The blend was tabletted using an F-press that was equipped with specially made caplet 
tooling, measuring 21.5mm by 10mm. Using an A&D HM120 balance (Oxford, UK), 
approximately 1.446g of blend was weighed out onto a plastic weighing boat and 
transferred to the die. The punches were turned over by hand to compact the tablet.
The punches were wiped clean after each compaction to avoid tablet capping.
■ Each tablet was made to a hardness of approximately 18KPa.
Approximately 50 tablets were made, and there were no obvious problems during
manufacture, which indicated that the alterations to the methodology were successful. The
tablets were then tested for uniformity.
5.6.1 Weight variation
The tablets were assessed according to the method outlined in section 2.3.5, page
15. Results are shown below in Table 8, page 83.
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Table 8 A table to show the weight variation in batch 2















The tablets had an average weight of 1.4417g and a standard deviation of 0.00127. This is 
an improvement on the results that were produced with blend 1 (Table 5, page 74). The 
improvement in the reproducibility of the tablet weight groupings was due to the improved 
blending methodology associated with this batch.
5.6.2 Hardness testing
The tablets were assessed according to the method outlined in section 2.3.4, page 
15. The results are shown below in Table 9, page 84.
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Table 9 A table to show the hardness variation in batch 2








The tablets had an average hardness of 16.8KPa, with a standard deviation of 0.883. The 
standard deviation of this batch of tablets is again lower than for the previous batch. This 
was also thought to be due to the improvement in the blending methodology. The tighter 
grouping of the results indicates that the blend, and therefore the tablets, is more 
homogenous than before. This increase in homogeneity will inevitably result in more 
reproducible tablets that will, in turn, provide more reproducible results during later 
testing.
5.6.3 Buoyancy testing
Five tablets from blend 2 were tested in the buoyancy apparatus to see if an 
improvement in correlation could be determined after changes to the blend methodology. 
The tablets were tested using the method outlined previously in section 3.8, page 33.






















The buoyancy profiles produced for the five tablet runs were again an order of 
magnitude different from the buoyancy seen due to water loss previously.
The profiles produced all followed a distinctive, four-phase pattern over the 
duration of the experiment. The four distinct patterns have been described previously on 
page 77.
At various points of the test all profiles can still be seen to exhibit the “jumping” 
effect seen previously. This was again thought to be due to bubbles of CO2 escaping from 
the polymer matrix and therefore their contribution to buoyancy suddenly being lost. All 
of the “jumps” show a loss of buoyancy, which would have been the case if gas were being 
lost from the system.
The graphs were assessed for reproducibility by measuring the area above each 
individual curve, as this area is a direct measurement of the buoyancy force exhibited by 
each tablet throughout the duration of the experiment. This method of integration was 
chosen as a quantitative technique due to the complex nature of the graphs. All buoyancy 
force data will be shown in gram hours (gh) for ease of comparison. Peakfit 4.06 for 
Windows was used to analyse the data sets and to produce the buoyancy force data shown 
in Table 10, page 86. The tablets showed a mean buoyancy force of 6.381gh during the 
experiment, with a standard deviation of 0.714.
Table 10 A table to show the buoyancy force data for blend 2









5.6.4 Pressure vessel testing
Five tablets from blend 2 were tested in the pressure vessel to assess the rate of 
carbon dioxide production from the formulation. The tablets were tested using the method 
outlined previously in section 4.9.1, page 58, with the tablet being added to the release 
mechanism before the vessel was sealed, and the tablet released into the medium after re­
zeroing of the pressure vent.
Results of the five tablet runs are shown in Figure 28, page 88. The graph shows 
the data sets from the re-zero point onwards until the end of the tests. The five runs show a 
similar profile of carbon dioxide release throughout the duration of the test. It can be seen 
that CO2 is still being released even after 7 hours of testing in all of the profiles. All tablets 
also show the most rapid phase of CO2 release to be immediately after immersion into the 
SGF. This is to be expected as the large surface area of the tablet hydrates, causing the 
sodium bicarbonate in the formulation to react with the hydrochloric acid in the medium. 
This burst of CO2 lasts for only a matter of minutes before subsiding for the subsequent 20- 
minute period. This 20 minute resting period is thought to be caused by a gel like barrier 
being formed on the outside of the tablet which slows down the penetration of the acidic 
SGF medium into the tablet core. Any fluid that does penetrate this gel layer may well 
have already been neutralised by the bicarbonate reaction that has taken place, resulting in 
a slowing of the CO2 reaction. Following this 20-minute period, CO2 is again slowly 
released until the end of the test. The rate of release initially increases before slowing from 
this point onwards. This was thought to be because the acid medium started to react with 
the tablet core, therefore re-initiating the production of CO2 gas. The rate of gas 
production decreases until the end the test due to the reduction of the surface area available 
for interaction as the tablet undergoes constant erosion in the vessel. Figure 29, page 89, 
shows the average pressure accumulated in the vessel for the five tablet runs. Also shown 
is the rate of pressure build up during consecutive 1.5-minute periods. The graph has been 
normalised so that the results can be plotted onto the same axis. The graph proves the 
initial hypothesis, that the peak gas release rate was during the first few minutes of the test. 
The rate of release then slows dramatically, before slowly peaking again after 


















Figure 29 A graph to show the rate of gas release during consecutive 1.5-minute periods for blend 2
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Table 11, page 90, shows a summary of the data. It can be seen from the table that 
all the tablets generated between 190 and 210 mbar of pressure over the 7.4-hour test 
duration. The small variation in results is simply due to the slightly different interaction of 
each individual tablet with the SGF as the experiment progresses. The average pressure 
generated per hour has also been calculated so that this batch can be compared with future 
formulations. The average pressure generated per hour for blend two varied between 25.72 
-  28.37 mbar.








generated per hour (mbar)
1 190.32 7.4 25.72
2 209.91 7.4 28.37
3 203.43 7.4 27.49
4 202.73 7.4 27.40
5 195.84 7.4 26.46
5.6.5 Mercury porosimetry
Runs were performed under the conditions discussed in 5.4.4, page 79, and tablets 
were tested according to the protocol outlined in paragraph 2.3.1, page 14. The tablets 
were tested in duplicate to assess reproducibility. See Table 12, page 91 for results.
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Table 12 A table to show the mercury porosimetry results for tablets made from 
blend 2











Porosity % 24.58 23.00 23.79
The results were seen to be reproducible for the two tablets. The bulk of the pores 
detected were between 0.1pm and 0.2pm in diameter, which correlated with the results 
seen previously for blend one. The bulk density of this set of tablets was 1.1663 g/ml, 
which indicates the tablets should have sunk when placed into the SGF medium, however 
the previous buoyancy data has shown that the tablets float upon immersion due to their 
immediate interaction with the gastric medium. Future blends will also be investigated 
using this technique to see if initial bulk density and pore size distribution has any affect on 
floating properties.
5.6.6 Nitrogen adsorption
The specific surface area of tablets is a parameter of interest when looking to 
characterise floating dosage forms. Specific surface areas can be measured using gas 
adsorption techniques, which depend on the ability to predict the number of adsorbate 
molecules required to exactly cover the surface of a material with a single molecule layer 
of inert gas (Brittain et al, 1991). One such technique is surface area analysis using 
nitrogen adsorption. This technique measures surface area and pore size based on the 
adsorption and desorption of nitrogen on the surface and into the pores of solids. An 
imbalance of atomic forces on the surface of a clean, evacuated solid attracts gas
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molecules. When these molecules collide with the surface, they either bounce off or 
adsorb. The period of time taken for a gas molecule to adsorb on to the surface of the solid 
depends on the energetics of the surface with which it collides, the physical and chemical 
nature of the sample and the gas, and the temperature of the sample. When molecules 
leave the bulk of the gas to adsorb onto the surface of a sample, the average number of 
molecules in the gas decreases; therefore, the pressure decreases. A pressure transducer 
within the apparatus detects this change in pressure and determines the number of 
molecules adsorbed from the gas. The instrument also measures the temperature of the gas 
and the volume of the container used, so that the data can be used to calculate the surface 
area and the pore size of the material being tested. The sorption isotherms produced are 
interpreted using the equation developed by Brunauer, Emmett and Teller (BET) (Brunauer 
and Emmett, 1937). The BET equation (Equation 4, page 92) is applied over the linear 
range of the P/P° graph.
Equation 4
P _  1 ( C - l ) P  
V(P0 - P ) ~ V mC + VmCP0
where V is the volume of gas adsorbed at pressure P, P is the partial pressure of nitrogen, 
Vm is the volume of nitrogen adsorbed in the monolayer, Po is the saturation pressure of 
nitrogen and C is a constant exponentially related to the heat of adsortion of the nitrogen 
gas on the sample. The surface area was determined as a product of the number of 
molecules in a completed monolayer and the effective cross-sectional area of nitrogen 





where St is the total surface area, No is Avogadro’s number, Acs is the cross sectional area 
of nitrogen (0.1620nm2) and M is the mass of the sample.
Three tablets from blend 2 were tested using the protocol outlined in section 2.3.2. 
The results for are shown below in Table 13, page 93.
Table 13 Results from BET surface area analysis on blend 2
Sample weight before 
outgassing (g)
Sample weight after 
outgassing (g)
BET surface area (m2/g)
4.3259 4.2298 3.1134
The BET value of 3.1134 m2/g that was recorded is a low value typical of many 
pharmaceutical excipients (Brittain et al, 1991). This value is lower than that predicted 
using mercury porosimetry, however this is expected as in pharmaceutical samples such as 
powders and tablets, total surface area values obtained with mercury porosimetry have 
been historically higher than those obtained with the gas adsorption method (Van Brakel et 
al, 1981). The existence of ink-bottle pores explains this phenomenon, as the narrow 
opening of the pores allows them only to be filled at the higher pressures present in 
mercury porosimetry. Another reason for the discrepancy is the different measurement 
ranges of the two techniques, with the gas adsorption technique looking at the smaller pore 
range (3-200nm). It is therefore necessary to use both techniques when analysing the 
surface area properties of tablets, so that all pore ranges can be assessed. Future blends 
will therefore be tested using both techniques to see whether surface area is affected by 
changes in the formulation. It will then be possible to see how important the initial pore 
size, structure and surface area are when trying to determine the floating characteristics of 
a dosage form.
When dealing with materials that have a low surface area it is usually prudent to 
use as much material as possible so as to improve correlation (Newman, 1995). However,
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increasing the amount of material being tested leads to a direct increase in the time needed 
to outgas the sample prior to testing. In the case of the tablets made from blend 2, the 
outgassing already took over 12 hours to complete, thus any increase in sample size would 
cause problems with the length of analysis time. It is possible to reduce analysis time by 
heating the sample during outgassing, but increased temperatures, especially under 
vacuum, can change the properties of organic materials (Newman, 1995). It was therefore 
decided to use this set of parameters for all future tests.
5.6.7 Development of an apparatus capable of quantifying tablet swelling
5.6.7.1 Introduction
The extent with which an excipient or formulation interacts with the medium 
surrounding it can have a direct effect on the ability of a dosage form to float, as well as 
having an effect on drug release. Density is inversely proportional to the volume of a 
dosage form, therefore if a tablet swells when immersed in medium, so the density of that 
dosage form will decrease correspondingly -  assuming that the mass of the system remains 
constant. The thickness of the gel that the swelling process produces will also have an 
effect on gas-powered floating dosage forms, as it would be preferential, for optimal 
floating, if the gel was capable of trapping gas in order to facilitate buoyancy. An in vitro 
method capable of measuring the swelling of a floating dosage form would therefore be of 
use to the formulator. The data from such a test could be used in conjunction with the data 
from previous experiments when trying to predict in vivo results. It is also necessary to be 
sure that a dosage form does not swell too much and hence potentially form a blockage in 
vivo.
A number of methods have been used to measure the swelling of floating dosage 
forms, including gravimetric (Gerogiannis et al, 1993) and photographic techniques. 
Talukdar and Kinget (1995) described one such test that had been designed to measure the 
swelling of dosage forms. Their work describes a technique for measuring both the axial 
and radial swelling of tablets. The radial swelling was measured by immersing the tablet 
into a beaker of 500ml of medium, underneath which was placed a piece of graph paper.
At defined time intervals, the increase in tablet diameter was determined using the 
divisions printed on the graph paper. This technique is flawed in terms of accuracy as the 
method necessitates looking through the test medium in order to see how much the tablet
94
had swollen. Obviously the medium will have a refractive index that will alter the 
accuracy of the results obtained. It would also not be a suitable method for floating dosage 
forms due to the distance that would be present between the tablet and the graph paper, 
adding to the inaccuracy of the system.
The method used for axial swelling was also inappropriate. It involved the use of a 
dial indicator placed on top of the tablet, however the indicator inhibited the swelling seen 
due to the force it exhibited on the polymer system.
It was therefore decided to produce a method capable of measuring the radial 
swelling of floating dosage forms accurately over the course of an 8-hour period 
(approximate gastric residence time in vivo).
5.6.7.2 Original apparatus design
One litre of simulated gastric fluid (SGF) was produced according to Formula 1, 
page 33, and was then degassed by bubbling helium through the mixture for 1 hour to 
remove any dissolved gasses. The SGF was then transferred to a glass vessel, situated on a 
Heidolph heated plate (Schwabach, Germany), and heated to 37°C. The temperature of the 
medium was controlled using a feedback control directed through a thermometer in the 
medium, linked to the hot plate. In the centre of the glass container was placed a smaller, 
blacked out, plastic vessel to house the tablet. The plastic vessel was weighed down using 
magnetic stirrers attached to the bottom of the structure. The plastic was blacked out to 
improve the contrast seen in the digital photographs that were to be produced. The plastic 
housing was machined to such a height that its peak was just underneath the meniscus of 
the SGF in the vessel. The diameter of the plastic housing was such that it would not 
restrict the swelling of a tablet, but small enough that the tablet would be unable to float 
out of view of the camera.
To measure the degree of swelling a wire mesh was added to the top of the plastic 
housing, so that the floating tablet would sit underneath the mesh. The mesh would then 
provide a grid like structure through which the size of the tablet could be easily measured.
A digital camera (Fujifilm DX7, Tokyo, Japan) was suspended, by a series of 
clamp stands, above the SGF so that the plastic housing and floating tablet could be clearly 
seen in the viewer. The camera was directly linked to a P.C., so that all pictures could be 
instantly downloaded and analysed on screen.
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5.6.7.3 Results from original apparatus
A digital photograph of the plastic housing and mesh prior to addition of a tablet 
can be seen in Figure 30, page 96. A tablet manufactured from blend 2 was then placed 
into the SGF and photographs were taken at 30-minute intervals for a period of 2 hours. 
Two photographs from this series can be seen in Figure 31, page 97. It can be seen from 
the photographs that the mesh worked well initially, both containing the floating tablet and 
acting as a useful measuring tool for swelling analysis. However, in the later photographs 
as the floating tablet breaks up, definition of the tablet boundary is lost, making analysis of 
swelling impossible. This brought the accuracy o f the technique into question, so it was 
decided to remove the mesh from the plastic housing.
Figure 30 A digital photograph of the housing structure and mesh
■ r a n * ? * !
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Figure 31 Two digital photographs showing the swelling of a blend 2 tablet
0 minutes
120 minutes
5.6.7.4 Modifications to the apparatus
Due to the removal o f the meshwork, swelling could be no longer be measured by 
simple grid occlusion. To overcome this problem it was decided to use the technique of 
image analysis.
Image analysis is a technique whereby the cross sectional area of the tablet can be 
measured directly from a digital photograph. Image analysis has previously been shown to 
be useful for measuring the bubble formation within an alginate raft preparation (Johnson 
et al, 1998). To ensure that accuracy of the technique is maintained it is necessary to
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calibrate the analyser prior to each calculation. To do this two perpendicular measurement 
gauges were integrated into the apparatus so that calibrated scales would appear on each 
digital photograph. The scales could then be used as a calibration tool for the image 
analyser. Before using the technique it was first necessary to calibrate the analyser both 
horizontally and vertically, before manually selecting the outside border of the swollen 
tablet. The image analyser then accurately calculated the cross-sectional area of the 
swollen tablet image.
5.6.7.5 Final methodology
■ One Litre of SGF was produced according to Formula 1, page 33. Helium was then 
bubbled through the SGF for 1 hour in order to remove all dissolved gasses.
■ The degassed SGF was transferred to the glass vessel and heated to 37°C.
■ The camera assembly and plastic housing were placed into position and the time set to 
zero.
■ A tablet from blend 2 was placed into the medium using a spatula and left to react with 
the medium.
■ Digital Photographs of the tablet were taken after 1,15, 30,45, 60, 90,120, 150,180, 
240, 300, 360, 420 and 480 minutes.
■ The photographs were subjected to image analysis to determine the cross-sectional area 
of the swollen tablet and therefore the radial swelling.
■ Tests were repeated in triplicate in order to assess reproducibility.
5.6.7.6 Results from blend 2
Sample digital photographs are shown below in Figure 32, page 99. Table 14, page 
100 shows the results of the image analysis for each run, along with average values. The 
data for time zero was taken by subjecting a dry control tablet to the image analysis 
process.
The data can be seen graphically in Figure 33, page 101. From the data we can see 
that all three runs show similar profiles. As expected the runs do not follow identical 
traces. This is because each individual tablet has a slightly different interaction profile 
with the SGF medium, despite all tablets being made to similar specifications initially.
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The overall profile of the three traces does, however, show similarities. Four distinct 
phases of interaction can be seen.
i. Initial rapid burst of swelling as the tablet begins to interact with the SGF in the first 
minute of the test.
ii. A prolonged decrease in the size of the tablet which continues up until the two and a 
half-hour period.
iii. A stabilisation of the tablet size that lasts until the four-hour mark.
iv. Further degeneration of the tablet that continues until the end of the test run.




















0 2.1711 2.1711 2.1711 2.1711 0.0000
1 2.5799 2.3106 2.7151 2.5352 0.2059
15 2.2729 2.0343 2.3579 2.2217 0.1678
30 1.9789 2.0054 2.2307 2.0717 0.1384
45 1.8978 1.7680 1.9276 1.8645 0.0849
60 1.7610 1.6993 1.8617 1.7740 0.0820
90 1.6367 1.5461 1.7563 1.6464 0.1054
120 1.5807 1.4500 1.7063 1.5790 0.1282
150 1.5197 1.3942 1.6335 1.5158 0.1197
180 1.5139 1.3757 1.6032 1.4976 0.1146
240 1.4924 1.3386 1.5856 1.4722 0.1247
300 1.4178 1.3008 1.4116 1.3767 0.0658
360 1.1910 1.1745 1.2348 1.2001 0.0312
420 1.1893 1.0459 1.0689 1.1014 0.0770
480 1.0701 0.9846 0.9973 1.0173 0.0461
1 0 0
- ♦ - T a b le t  1 
- ■ “ Tablet 2 
- ♦ “ Tablet 3
Phase i. of the graph, as described above, is due to the initial interaction of the dry 
tablet with the SGF. The outside of the tablet swells rapidly as the polymers in the matrix 
hydrate and the sodium bicarbonate interacts with the SGF to produce carbon dioxide. The 
carbon dioxide acts as a disintegrant and forces the tablet to expand to accommodate the 
gas. Some of the carbon dioxide escapes from the matrix, whilst some is thought to remain 
trapped in the polymer network. It is the combination of these effects that cause the initial 
burst of swelling as the dry tablet is submerged.
Phase ii. of the graph is seen as the tablet extremes begin to erode away from the 
tablet core, perhaps partly due to the disintegrant effect. The polymer matrix becomes 
looser and detaches from the bulk of the tablet. A shrinking effect is therefore seen.
Phase iii. of the graph can be described as a regeneration phase. It occurs when the 
initial layer of swollen matrix has been eroded from the core, and a second layer of dry 
matter begins to interact with the SGF medium. This second swelling phase is, however, 
countered by the constant erosion that is occurring, which produces this static phase of 
“growth”.
Phase iv. is the final phase of degeneration that occurs as the erosion becomes 
quicker than the swelling phase and the tablet begins to shrink. This phase then continues 
until the entire tablet has disintegrated.
5.6.8 Discussion of blend 2 characteristics
Each test has so far been discussed in isolation, however it is the integration of all 
the tests to produce a complete overview that is the aim of this project. This section will 
attempt to bring together the data amassed so far, in order to explain the behaviour of blend 
2 as a floating dosage form. This data will enable us to assess the specific details that 
enable blend 2 to float successfully for a duration of 8-hours. It will also enable us to see if 
the assembled barrage of in vitro tests yield enough information to identify the various 
factors that lead to the development of a floating dosage form.
The tests that have been conducted fall into two main categories:
1) Initial dry tablet characterisation
2) Dynamic wet tablet characterisation
The dry characterisation tests were essential to ensure that the tablets produced for 
blend 2 were as similar as possible. Both weight variation and hardness testing were
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chosen as standard parameters for tablet processing quality control. The aim was to 
produce tablets with a weight of 1.44g and an approximate hardness of 17-18KPa. The 
tablets that were produced had an average weight of 1.4417g, with a standard deviation of
0.00127, and an average hardness of 16.8KPa, with a standard deviation of 0.883. These 
values were deemed more than adequate for the purposes of this study.
The second part of the dry testing was concerned with the surface area and pore 
size distribution of the tablets. Mercury porosimetry and nitrogen adsorption techniques 
were utilised to derive this information. The available surface area and pore size 
distribution may be important in determining the speed with which dosage forms interact 
with the SGF in the dynamic tests. It was discovered, however, that the surface areas 
present in the blend 2 tablets were small, which is in correlation with many other 
pharmaceutical products. The problem with pre-measuring the surface area and pore size 
of these tablets is highlighted by the dynamic changes that the tablets undergo when 
submerged in the SGF. The tablets undergo a dramatic change in structure that is likely to 
be more due to the blend formulation than the initial pore size / surface area. The 
relationship between initial surface area, pore size and buoyancy will be discussed in a 
future chapter after further formulations have been assessed. It is likely however, that the 
only way to assess whether varying surface area and / or pore size has an effect on initial 
buoyancy results, would be to produce tablets with the same formulation but varying 
surface areas. This is not within the scope of this project, but we will continue to utilise 
the mercury porosimetry and nitrogen adsorption results as a means of quality control.
The dynamic stage of testing is obviously the most pertinent to this work. Three 
different tests were performed to study the factors that lead to buoyancy. These were the 
resultant weight, the rate of gas production and the continuous swelling of the dosage form. 
By choosing these three parameters we are able to combine the results to try to understand 
why the formulation floats with a different force at particular stages of its interaction with 
SGF. This information will then enable understanding as to why particular formulations 
float for longer than others in vivo, enabling a better understanding of the results of 
previous in vivo work.
It is perhaps the profile of the graphs that are produced which tell us most about the 
dynamic changes occurring within the tablet during testing. Figure 34, page 106, shows 
the average data from all three dynamic tests. The data sets have been normalised in order 
to show the data on the same axis. The buoyancy graph shows positive data, e.g. the 
average resultant weight exhibited by the tablets. The swelling data is simply the average
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data for the five tablets, whilst the pressure data shows the average normalised gradient 
(e.g. the normalised rate of gas release) of the pressure build up in the pressure vessel. The 
pressure gradient was calculated using 90-second intervals throughout the duration of the 
test.
It is seen that, as expected, the buoyancy graph can be fully explained from the 
swelling and rate of gas release graphs. As discussed before the buoyancy profile of the 
tablets can be broken down into four main sections:
1. An initial peak buoyancy period as soon as the tablets are immersed in the SGF 
medium.
2. After the initial buoyancy period, a rapid decrease in buoyancy until approximately 30 
minutes has passed.
3. A second, slower buoyancy increase then becomes apparent in the trace. This increase 
continues until approximately 1-1.5 hours after the start of the experiment.
4. After 3 hours, until the end of the test, the resultant weight is seen to decrease steadily.
These four distinct sections of the buoyancy profile occurred reproducibly for all tablets 
tested. It is possible to use the dynamic testing data to fully explain this distinctive profile. 
Below is a summary of the changes that the tablet undergoes during the floating process, 
with each step being used to explain to the four sections of buoyancy that are seen:
1. It can be seen from the graphs that the initial buoyancy peak is a combination of the 
polymers within the tablet swelling and CO2 gas production. Swelling of the tablet 
possibly increases buoyancy due to a corresponding decrease in the density of the 
dosage form, caused by the increase in volume. The gas production also inevitably 
adds to the buoyancy effect seen initially as some of the gas produced when the 
bicarbonate reacts with the acid medium is trapped within the polymer network of the 
tablet, therefore helping the tablet to float.
2. This period comes about as the tablet, having swollen to its peak size, begins to 
undergo erosion in the SGF. Though the tablet is still producing gas, the rate of 
production has also slowed dramatically during this period. This loss of gas production 
inevitably results in a loss of buoyancy to the tablet. The gas previously generated, and 
trapped, is slowly released as the polymer matrix relaxes, and as the rate of gas
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evolution has slowed, there is no more gas to replace the lost CO2 . The release of this 
gas therefore causes the density of the tablet to increase, reducing the buoyancy effect.
3. The second phase of buoyancy increase is directly correlated to the second increase in 
gas production rate (see Figure 34, page 106). This increase in CO2 release is possibly 
due to the erosion of the initial tablet front. As the tablet erodes, acid in the SGF is 
able to react with previously stable sodium bicarbonate, causing an increase in gas 
production from the blend. Some of this gas will again be trapped in the polymer 
matrix of the tablet causing a decrease in the density of the dosage form.
4. The final phase starts with a stabilisation of buoyancy followed by a decrease until 
completion of the test. The stabilisation phase is due to the size of the tablet remaining 
constant during this period. There is a slight decrease in buoyancy, caused by the 
slowing down of gas evolution, which is seen until the end of the test. This is due to 
the tablet again eroding away, in conjunction with the constant slowing of gas 
production. During this period more gas will be escaping from the matrix of the tablet, 
with less and less gas being produced to replace it. However, all tablets were buoyant 
throughout the duration of the test.
Following the development of the dynamic in vitro testing methodology and 
utilisation of the equipment to produce results capable of explaining the behaviour of a 
floating dosage form, it was decided to test the ability of the apparatus to detect small 
changes in tablet formulation. It was decided to produce two blends similar to blend two 
for testing purposes, and to investigate the effect on buoyancy that altering the blend 
formulation had. It will also test the robustness of the methodology, as the dosage forms 
will still be quite similar in their make up. The next section will also attempt to rationalise 
the findings and hypothesise on what changes should be made to the formulation to 










Figure 34 A graph to show the normalised dynamic testing data sets for blend 2
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5. 7 Formulation and testing of secondary blends
It was decided to test two further blends to assess if the apparatus were capable of 
distinguishing between similar formulations. It was also necessary to assess these dosage 
forms to ensure that the dynamic testing methodologies could provide accurate information 
capable of explaining the individual floating profiles shown by specific formulations.
Blend 2 was used as the control around which the new formulations were 
developed. It was decided that one of the most important components of the floating 
formulation was the inclusion of sodium bicarbonate. The sodium bicarbonate would 
therefore make an ideal parameter for alteration within the new blends. Using blend 2 as 
the reference point, it was decided to use twice as much sodium bicarbonate in blend 3 
(400mg per tablet) and half as much in blend 4 (lOOmg per tablet).
It was felt that it would be important to keep the weight of the tablets, and the ratio 
of excipients, equal throughout the testing protocols, therefore it was also necessary to 
change another constituent of the blends in an equal and opposite way to that of the sodium 
bicarbonate. The parameter that was thought to be contributing least to the floating 
process was the active ingredient (ciprofloxacin) in the blend. The ciprofloxacin was 
therefore reduced in such a way as to keep the weight of the tablets in blends 3 and 4 equal 
to those in blend 2. The formulation of blends 3 and 4 are shown in Table 15, page 107.
Table 15 Blend constituents of formulations 3 and 4
Excipient Blend 3 (mg per tab) Blend 4 (mg per tab)
Ciprofloxacin 800 1100
Sodium Alginate 5 5
Xanthan Gum 15 15






Total Weight 1440 1440
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In the next section the blends will be assessed individually using the dynamic 
testing mechanisms and basic tablet testing theories, used for blend 2. The formulations 
will then be compared to assess both the robustness of the testing regimes, and the effect 
that changing the amount sodium bicarbonate in the blend has on floating. It should also 
be possible to explain how the alterations to the blend have affected the buoyancy profile, 
and to suggest how the current blend could be improved for future use.
5.7.1 Results from blend 3
The formulation of blend 3 is shown in Table 15, page 107. The blend was 
prepared and made into tablets using the protocol outlined in Section 5.6., page 81. As 
before, approximately 150g of the blend was made and tabletted. No obvious problems 
were encountered during manufacture. The tablets were then tested for uniformity.
5.7.1.1 Weight variation
The tablets were assessed according to the method outlined in section 2.3.5, page 
15. Results are shown below in Table 16, page 109.
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Table 16 A table to show the weight variation in batch 3















The tablets had an average weight of 1.4424g and a standard deviation of 0.000698. The 
tablet weights from this batch were closely grouped and deemed appropriate for the study.
5.7.1.2 Hardness testing
The tablets were assessed according to the method outlined in section 2.3.4, page 
15. The results are shown below in Table 17, page 110.
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Table 17 A table to show the hardness variation in batch 3








The tablets had an average hardness of 17.94KPa, with a standard deviation of 0.365. The 
standard deviation of this batch of tablets is again low. The tight grouping of the results 
indicates that the blend and therefore the tablets are homogenous. This homogeneity will 
help to provide reproducible results during dynamic testing.
5.7.1.3 Buoyancy testing
Five tablets from blend 3 were tested in the buoyancy apparatus to ascertain the 
effect of changing the levels of sodium bicarbonate in the tablets. Five tablets were tested 
to further assess the reproducibility of the apparatus and testing methodology. The tablets 
were tested using the method outlined previously in section 3.8, page 33.

























The profiles produced all followed the distinctive, four-phase pattern over the 
duration of the experiment. The four-phase pattern has been described previously on page 
77. However, the duration of each phase differed from previous blends. It can be seen 
from the graphs that tablets from blend 3 begin to enter phase four after only 1 hour has 
passed, compared with the 3 hours seen with blend 2 tablets. It is possible that the phase 
time has been reduced due to the increase in sodium bicarbonate content in the blend 3 
tablets.
It can also be seen from the graph that the peak buoyancy, which occurs during the 
first few minutes of the test, is greater when using this set of tablets. Again this is thought 
to be due to the increase in the sodium bicarbonate content reacting with the acid medium 
and driving the tablet upwards through its buoyant effect. After 8 hours, the graph shows 
that the 5 tablet runs are all exhibiting less buoyancy than that seen with blend 2 tablets. 
This decrease does not correlate with the increased quantity of sodium bicarbonate present 
in the tablets, as it would be expected that more CO2 would be released throughout the test, 
which should aid buoyancy. However, it seems in this case that most of the sodium 
bicarbonate has already reacted before the test has finished.
Throughout the test all profiles exhibit a wildly fluctuating buoyancy reading. This 
fluctuation is greater than that of the previous blend. This was again thought to be due to 
bubbles of CO2 escaping from the polymer matrix and therefore their contribution to 
buoyancy suddenly being lost, however, as we expected the rate of CO2 to increase with 
this blend, this should come as no surprise. All of the “jumps” are once again showing a 
loss of buoyancy which is what we would expect if gas were being lost from the dosage 
form.
The graphs were assessed for reproducibility by measuring the area above each 
individual curve, as this area is a direct measurement of the buoyancy force exhibited by 
each tablet throughout the duration of the experiment. Peakfit 4.06 for Windows was again 
used to analyse the data sets and to produce the buoyancy force data shown in Table 18, 
page 113. The tablets showed a mean buoyancy force of 4.987gh during the experiment, 
with a standard deviation of 0.981.
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Table 18 A table to show the buoyancy force data for blend 3








5.7.1.4 Pressure vessel testing
Five tablets from blend 3 were tested in the pressure vessel to assess the rate of 
carbon dioxide production from the formulation. The tablets were tested using the method 
outlined previously in section 4.9.1, page 58, with the tablet being added to the release 
mechanism before the vessel was sealed, and the tablet released into the medium after re­
zeroing of the pressure vent.
Results of the five tablet runs are shown in Figure 36, page 115. The graph shows 
the data sets from the re-zero point onwards until the end of the tests. The five runs show a 
similar profile of carbon dioxide release throughout the duration of the test. The rate of 
CO2 release for this blend is greater than for blend 2, which is what would have been 
expected due to the increased percentage of sodium bicarbonate present in blend 3. In fact, 
the amount of CO2 released by the tablets soon exceeds the internal calibration limits of the 
pressure vessel. The limit is exceeded 1 .5 -2  hours after the tests started. The gas release 
rate for this batch can therefore only be measured for the length of time that the pressure 
remains within the calibration limits of the vessel.
All tablets still show the most rapid phase of CO2 release to be immediately after 
immersion into the SGF. This is due to the large surface area of the tablet rapidly 
hydrating, causing the sodium bicarbonate near to the surface of the tablet to react with the 
hydrochloric acid in the medium. The resulting burst of CO2 lasts for only a couple of 
minutes before subsiding for the subsequent 20-minute period. The 20 minute resting
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period is thought to be due to a gel barrier being formed on the outside of the tablet which 
slows down the penetration of the acidic SGF medium into the tablet core. After this 20- 
minute period, CO2 again begins to be released until the end of the test. The rate of release 
increases initially before slowly decreasing from this point onwards. This phase of gas 
release is thought to be due to the acid medium reacting with the previously shielded core 
of the tablet, therefore re-initiating the production of CO2 gas. The rate of gas production 
decreases until completion of the test due to the diminishing size of the surface area 
available for interaction with the medium as the tablet undergoes constant erosion.
Figure 37, page 116, shows the average pressure accumulated in the vessel for the 
five tablet runs. Also shown is the rate of pressure build up during consecutive 1.5-minute 
periods. The graph has been normalised so that the results can be plotted onto the same 
axis. The graph confirms that the peak gas release rate was during the first couple of 
minutes of the test. The rate of release then slows dramatically, before peaking again after 
approximately half an hour. The gas release rate then slows down continuously until the 
end of the test. Each phase of the gas release follows the same profile as blend 2, however 
blend 3 undergoes each phase over a shorter period of time.
Table 19, page 117, shows a summary of the data. It can be seen from the table 
that all tablets easily generated 210 mbar of pressure, the maximum pressure that the vessel 
could accurately measure. Each tablet took a slightly different time to achieve this 
pressure; the variation in time being due to the slightly different dynamic interaction of 
each tablet with the simulated gastric fluid. It should be noted that the maximum pressure 
generated by this set of tablets was determined by the calibration restriction of the pressure 
vessel, not by the amount of CO2 being produced by the tablets. If the vessel had been able 
to measure higher pressures, then it would have shown that these tablets produced 
pressures in excess of 210 mbar. The average pressure generated per hour has therefore 
been calculated in order to enable the rate of gas release for this batch to be compared with 
other batches. The average pressure generated per hour for blend three varied between 
99.45 -  141.88 mbar.
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Figure 37 A graph to show the rate of gas release during consecutive 1.5-minute periods for blend 3
 pressure












generated per hour (mbar)
1 209.99 1.86 112.90
2 209.98 1.48 141.88
3 209.89 1.63 128.77
4 209.97 1.93 108.79
5 209.83 2.11 99.45
5.7.1.5 Mercury porosimetry
Runs were performed under the conditions discussed in 5.4.4, page 79, and tablets 
were tested according to the protocol outlined in paragraph 2.3.1, page 14. The tablets 
were tested in duplicate to assess reproducibility. See Table 20, page 118 for results.
The results for the two tablets were seen to be reproducible, as expected. The bulk 
of the pores detected were between 0.1pm and 0.2pm in diameter, which correlated with 
the results seen previously when analysing blend 2. The bulk density of this set of tablets 
was 1.2827g/ml, which indicates the tablets should again sink when they are placed into 
SGF medium. We have already seen from the buoyancy data that the tablets float almost 
as soon as they are immersed into the SGF medium, which indicates the overriding factor 
for floating is the dynamic interaction rather than the initial specifications.
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Table 20 A table to show the mercury porosimetry results for tablets made from
blend 3











Porosity % 21.56 21.74 21.65
5.7.1.6 Nitrogen adsorption
Three tablets from blend 3 were tested using the protocol outlined in section 2.3.2. 
The results for are shown below in Table 21, page 119.
The BET value of 6.1691 m /g that was recorded is again a low value that is typical 
of pharmaceutical excipients. This value is lower than the value determined using mercury 
porosimetry. The existence of ink-bottle pores has been one explanation for this 
phenomenon. However, the main reason for the discrepancy is the different measurement 
ranges of the two techniques, with the gas adsorption technique looking only at the smaller 
pore range (3-200nm).
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Table 21 Results from BET surface area analysis on blend 3
Sample weight before 
outgassing (g)
Sample weight after 
outgassing (g)
BET surface area (m2/g)
4.3246 4.2112 6.1691
The results from the gas sorption study show that the surface areas of the tablets 
from blend 3 are similar to those of blend 2. The results both show that a pore network is 
available within the tablets, despite the compression necessary to initially compact the 
tablets. This pore network should allow the tablets to rapidly hydrate upon immersion into 
the simulated gastric fluid. We have already seen from the buoyancy studies that this is the 
case, however it is hard to assess how much of this is down to the pore networks, as the 
tablets rapidly change their characteristics as they dynamically interact with surrounding 
medium. We can therefore only use these characterisation studies to measure initial bulk 
characteristics and to ensure that all blends have similar profiles before testing.
5.7.1.7 Swelling studies
Tablets from blend 3 were tested according to the protocol outlined in section 
5.6.7.5, page 98.
Sample digital photographs from the study are shown below in Figure 38, page 
120. Table 22, page 121 shows the results of the image analysis for each run, along with 
average values. The data for time zero was taken by subjecting a dry control tablet to the 
image analysis process.
The data can be seen graphically in Figure 39, page 122. From the data we can see 
that all three runs show similar profiles. As expected the runs do not follow identical 
traces, due to each individual tablet having a slightly different interaction profile with the 
SGF medium. The overall profiles of the three traces do, however, show similarities.
Three distinct phases of interaction can be seen.
i. Initial rapid burst of swelling as tablet begins to interact with the SGF within the 
first minute of the test.
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ii. A rapid decrease in the size of the swelling that continues up until the three-hour 
mark.
iii. A further, slower degeneration of the tablet that continues until the end of the 8- 
hour test run.
























0 2.1711 2.1711 2.1711 2.1711 0.0000
1 2.8493 2.8260 2.9028 2.8593 0.0394
15 2.7788 2.6544 2.6645 2.6992 0.0691
30 2.7485 2.6330 2.5003 2.6272 0.1242
45 2.5233 2.6131 2.3117 2.4827 0.1547
60 2.3746 2.3211 2.2911 2.3289 0.0423
90 2.2380 2.2257 2.1343 2.1993 0.0567
120 1.9243 1.8892 2.0401 1.9512 0.0790
150 1.8263 1.6028 1.8321 1.7537 0.1307
180 1.7486 1.5486 1.6974 1.6648 0.1039
240 1.6046 1.3898 1.6391 1.5445 0.1351
300 1.5509 1.3030 1.5877 1.4805 0.1548
360 1.4005 1.2705 1.534 1.4016 0.1318
420 1.3549 1.2594 1.5025 1.3722 0.1225
480 1.3202 1.2017 1.4672 1.3297 0.1330
Phase i. of the graph, as described above, is due to the rapid, initial interaction of 
the dry tablet with the SGF. The polymers in the matrix hydrate making the outside of the 
tablet swell rapidly, and the sodium bicarbonate also interacts with the SGF to produce 
carbon dioxide. The carbon dioxide produced acts as a partial disintegrant and forces the 
tablet to expand to accommodate the gas. Some of the carbon dioxide is lost from the 
matrix, whilst remains trapped in the polymer network. It is the combination of these 
effects that cause the initial burst of swelling.
Phase ii. of the graph is seen as the outside of the tablet begins to erode away from 
the tablet core, perhaps partly due to the power of the disintegrant effect. The polymer 
matrix becomes looser and detaches from the bulk of the tablet. A rapid shrinking effect is 
therefore seen.
Phase iii. is the final phase of degeneration that occurs after the swelling phase has 
























5.7.2 Discussion of blend 3 characteristics
Thus far the characteristics of the tablets from blend 3 have been investigated and 
discussed on an individual test basis, however it is the aim of this work to utilise these 
results to elucidate the mechanisms of a tablets in vitro floating properties. This section 
will attempt to bring together the data amassed so far, in order to explain the behaviour of 
blend 3 as a floating dosage form. The data will enable us to assess the combination of 
features that allow blend 3 to float successfully for an 8-hour period.
As discussed previously the tests that have been conducted fall into two main 
categories:
1) Initial dry tablet characterisation
2) Dynamic wet tablet characterisation
The initial dry characterisation tests were an important section of the work. The 
tests ensure that the tablets that had been produced from blend 3 were as similar to each 
other as possible. Both weight variation and hardness testing were chosen as standard 
parameters for tablet processing quality control, as these parameters are used throughout 
the pharmaceutical industry.
The aim was to produce tablets with an average weight of 1.44g and an 
approximate hardness of between 17-18KPa. The tablets that were produced had an 
average weight of 1.4424g, with a standard deviation of 0.00070, and an average hardness 
of 17.9KPa, with a standard deviation of 0.365. These ranges were deemed to be 
appropriate for the studies.
The second part of the dry testing was concerned with the surface area and pore 
size distribution of the tablets. Mercury porosimetry and nitrogen adsorption techniques 
were again utilised to derive this information. The available surface area and pore size 
distribution may be of importance in determining how quickly the dosage forms interact 
with the surrounding gastric medium during dynamic testing. The tests showed that the 
tablets from blend 3 had a relatively small surface area. It is thought, therefore, that the 
relationship between initial surface properties and dynamic properties are not very strong, 
due to the rapid changes that the tablets undergo once they are submerged in SGF. The 
tablets undergo a dramatic change in structure that is likely to be due more to the blend 
formulation than the initial pore size / surface area.
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The dynamic stage of testing is obviously the most relevant to this work. Three 
different tests were performed to study the factors that lead to buoyancy, the resultant 
weight, the rate of gas production and the continuous swelling of the dosage form. By 
choosing these parameters it is possible to study the results, and the relationship between 
them, to try to understand why the formulation exhibits a particular floating force at 
particular stages of its interaction with SGF. This information will allow an understanding 
as to why some formulations float for longer than others in vivo, which will enable a better 
understanding of the results from previous in vivo work.
In order to totally understand the dynamic changes that occur within the tablet 
during testing, it is necessary to study the profile of the graphs that have been produced 
from the multiple runs. Figure 40, page 126, shows the average data from all three 
dynamic tests. The data sets have been normalised in order to show the data on the same 
axis. The buoyancy graph shows the average resultant weight exhibited by the tablets.
The swelling data is the average data for the five tablets, whilst the pressure data shows the 
average normalised gradient (e.g. the normalised rate of gas release) of the pressure build 
up in the pressure vessel. The pressure gradient was calculated using 90-second intervals 
throughout the duration of the test. The data for the gas release is only shown for the first 
90 minutes of testing as the amount of gas released was exceeded the calibration limits on 
the pressure vessel.
It is seen, as expected, that the buoyancy graph can be fully explained from the 
swelling and rate of gas release graphs. As discussed previously the buoyancy profile of 
the tablets can be broken down into four main sections:
1. An initial peak buoyancy period once the tablets are immersed in the SGF medium.
2. After the initial buoyancy period, a rapid decrease in buoyancy until approximately 10 
minutes has passed.
3. A second, rapid buoyancy increase then becomes apparent. This increase continues 
until approximately 25 minutes after the start of the experiment.
4. After 25 minutes, until the end of the test, the resultant weight decreases steadily.
These four distinct phases of the buoyancy profile occurred reproducibly for all tablets 
tested. It is possible to use the dynamic testing data to fully explain this distinctive profile. 
Below is a summary of the changes that the tablets undergo during the floating process, 
with each step being used to explain to the four sections of buoyancy profile that are seen:
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1 The graphs show the initial peak of buoyancy is a combination of the polymers within 
the tablet swelling and CO2 gas production. The tablet swelling inevitably results in an 
increase in the buoyancy effect due to the relationship present between volume and 
density. Gas production also adds to the buoyancy effect as some of the gas produced 
by the bicarbonate reacting with the acid medium will be trapped within the polymer 
network of the tablet, ultimately helping the tablet float. The gas release rate and the 
degree of swelling are both at their highest level during the first few minutes of the test, 
which explains why the initial buoyancy of the tablets is so strong.
2 At this point the tablet is still producing gas, but the rate has slowed dramatically. This 
loss of gas production inevitably results in a direct loss of tablet buoyancy. Gas 
generated, and trapped in the polymer matrix, begins to be slowly released as the 
matrix relaxes. This loss of carbon dioxide from the polymer system results in a 
density increase, reducing its buoyancy in the SGF. The tablet is also undergoing a 
degree of erosion as the initial swelling begins to subside, adding to the increase in 
density.
3 The secondary phase of buoyancy increase directly correlates to the second increase in 
gas production rate. This increase in CO2 release is due to erosion of the swollen tablet 
front. As the tablet erodes the acid in the SGF can react with previously protected 
sodium bicarbonate, causing an increase in gas production from the blend. Some of 
this gas again gets trapped within the new polymer matrix front of the tablet and 
increases the buoyancy of the dosage form. During this phase the tablets continued to 
erode steadily in the vessel, but the rapid increase in gas production was more than 
enough to overcome this effect.
4 The last phase shows a continuous decrease in buoyancy until completion of the test. 
Again there is correlation with a decrease in gas production rate. Unfortunately it was 
not possible to monitor the evolution of the gas until the end of the test due to the 
pressure vessel calibration limitations. It can however be seen that the tablets 
continued to erode, indicating that any gas previously trapped in the polymer network 
will have been slowly released into the SGF medium. Despite this, all tablets were 





















The tablets were assessed according to the method outlined in section 2.3.4, page 
15. The results are shown below in Table 24, page 128.
Table 24 A table to show the hardness variation in batch 4








The tablets had an average hardness of 18.64KPa, with a standard deviation of 0.555. The 
standard deviation of this batch of tablets is again low. The tight grouping of the results 
indicates that the tablets are homogenous, which should lead to reproducible results during 
dynamic testing.
5 .133  Buoyancy testing
Five tablets from blend 4 were tested in the buoyancy apparatus to further assess 
the effect of changing the levels of sodium bicarbonate in the tablets. The tablets were 
tested using the method outlined previously in section 3.8, page 33.
The results are shown graphically in Figure 41, page 129.
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5.7.3 Results from blend 4
The formulation of blend 4 is shown in Table 15, page 107. The blend was 
prepared and made into tablets using the protocol outlined in Section 5.6., page 81. As 
before, approximately 150g of the blend was made and tabletted. No obvious problems 
were encountered during manufacture. The tablets were tested for uniformity.
5.7.3.1 Weight variation
The tablets were assessed according to the method outlined in section 2.3.5, page 
15. Results are shown below in Table 23, page 127.
Table 23 A table to show the weight variation in batch 4















The tablets had an average weight of 1.4389g and a standard deviation of 0.001236. The 


















The profiles produced followed the distinctive, four-phase pattern, which has been 
present in all blends, over the duration of the experiment. The four-phase pattern has been 
described previously on page 77. However, as with blend 3, the duration of each phase 
lasted for a different time. The graph shows that tablets from blend 4 begin to enter phase 
four after approximately 4 hours have passed, compared with the 3-hour period seen with 
the blend 2 tablets. It is likely this phase time has been increased due to the reduction in 
sodium bicarbonate content in the blend 4 tablets.
It can also be seen that the peak buoyancy, which still occurs during the first few 
minutes of the test, is reduced when using this set of tablets. Again this is due to the 
decrease in the sodium bicarbonate content resulting in a reduced reaction with the acid 
medium therefore decreasing the buoyant effect. After 8 hours, the graph shows that the 5 
tablets are all still exhibiting a buoyant effect. The buoyancy seen at this time is similar to 
that of the blend 3 tablets, but less than that of the blend 2 tablets
There is less fluctuation in the buoyancy readings throughout this test than in 
previous runs. This was thought to be due to fewer bubbles of CO2 escaping from the 
polymer matrix, which previously resulted in their contribution to buoyancy being 
suddenly lost. This had been expected due to the decrease in the sodium bicarbonate 
content of the blend.
The graphs were assessed for reproducibility by measuring the area above each 
individual curve, as a direct measurement of the buoyancy force exhibited by each tablet 
throughout the duration of the experiment. Peakfit 4.06 for Windows was once again used 
to analyse the data sets and to produce the buoyancy force data shown in Table 25, page 
131. The tablets showed a mean buoyancy force of 2.11 lgh during the experiment, with a 
standard deviation of 0.3432.
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Table 25 A table to show the buoyancy force data for blend 4








5.13 A  Pressure vessel testing
Five tablets from blend 4 were tested in the pressure vessel to assess the rate of 
carbon dioxide production from the formulation. The tablets were tested using the method 
outlined previously in section 4.9.1, page 58, with the tablet being added to the release 
mechanism before the vessel was sealed, and the tablet released into the medium after re- 
zeroing via the pressure vent.
Results of the five tablet runs are shown in Figure 42, page 133. The graph shows 
the data sets from the re-zero point onwards until the end of the tests. The five runs show a 
similar profile of carbon dioxide release throughout the duration of the test. The rate of 
CO2 release for this blend is slower than for the previous blends, which is what was 
expected due to the decreased percentage of sodium bicarbonate present in the blend.
The most rapid phase of gas release is still immediately after immersion into the 
SGF. This is again due to the large surface area of the tablet hydrating rapidly, causing the 
sodium bicarbonate near the surface to react with the hydrochloric acid in the SGF 
medium. The resulting burst of CO2 lasts for only a short period before subsiding for the 
subsequent 20-minute period. The 20 minute resting period is thought to due to the 
formation of a gel barrier on the outside of the tablet slowing the penetration of the acidic 
SGF medium into the tablet core. After this 20-minute period, CO2 is again released until 
the end of the test. The rate of release increases initially before slowly decreasing from 
this point onwards. This phase of gas release is attributed to the acid medium reacting with
131
the previously shielded tablet core, therefore re-initiating CO2 production. The rate of gas 
production then decreases until the end the test due to the diminishing size of the surface 
area available for interaction with the medium as the tablet undergoes constant erosion.
Figure 43, page 134, shows the average pressure that accumulated in the vessel for 
the five tablet runs. Also shown is the rate of pressure build up during consecutive 1.5- 
minute periods. The graph has been normalised such that the results can be plotted onto 
the same axis. The graph confirms the peak gas release rate was during the first couple of 
minutes of the test. The rate of release then slows dramatically, before peaking again after 
approximately half an hour. The gas release rate then stabilises for the next 3 hours before 
gradually decreasing towards the end of the test. Each phase of the gas release follows the 
same profile as previous blends.
Table 26, page 132, shows a summary of the data. It can be seen that the tablets 
generated between 102.2 and 112.5 mbar of pressure throughout the duration of the 
experiment. The variation in pressure is due to the slightly different interactions of each 
tablet with the simulated gastric fluid. The average pressure generated per hour has also 
been calculated to enable the rate of gas release for this batch to be compared with other 
batches. The average pressure generated per hour for blend 4 varied between 13.67 -
15.03 mbar.









1 107.02 7.48 14.31
2 112.44 7.48 15.03
3 110.02 7.48 14.71
4 106.68 7.48 14.26





































Runs were performed under the conditions discussed in 5.4.4, page 79, and tablets 
tested according to the protocol outlined in paragraph 2.3.1, page 14. The tablets were 
tested in duplicate to assess reproducibility. See Table 27, page 135 for results.
Table 27 A table to show the mercury porosimetry results for tablets made from 
blend 4











Porosity % 22.62 22.46 22.54
The results for the two tablets were seen to be reproducible, as expected. The bulk 
of the pores detected were between 0.1pm and 0.2pm in diameter, which correlated with 
previous blends. The bulk density of this set of tablets was 1.1632g/ml, which indicates 
that the tablets should again sink are placed into SGF medium. We have already seen from 
the buoyancy data that the tablets float almost as soon as they are immersed into the SGF 
medium, indicating that the overriding factor for floating is the dynamic interaction rather 
than the initial specifications.
5.7.3.6 Nitrogen adsorption
Three tablets from blend 4 were tested using the protocol outlined in section 2.3.2. 
The results for are shown below in Table 28, page 136.
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Table 28 Results from BET surface area analysis on blend 4
Sample weight before 
outgassing (g)
Sample weight after 
outgassing (g)
BET surface area (m2/g)
4.3263 4.2147 6.0185
The BET value of 6.0185 m2/g was again lower than the value determined using 
mercury porosimetry, due to the different measurement ranges of the two techniques.
The results from the gas sorption study show that the surface areas of the tablets 
from blend 4 are similar to those of the two previous blends. As discussed previously 
these characterisation studies are only being used to measure initial bulk characteristics and 
to ensure that all blends have similar profiles before dynamic testing.
5.13.1 Swelling studies
Tablets from blend 4 were tested according to the protocol outlined in section
5.6.7.5, page 98.
Sample digital photographs from the study are shown below in Figure 44, page 
137. Table 29, page 138 shows the results of the image analysis for each run, along with 
average values. The data for time zero was taken by subjecting a dry control tablet to the 
image analysis process.
The data can be seen graphically in Figure 45, page 139. From the data we can see 
that all three runs show similar profiles. As seen with previous blends, the runs do not 
follow identical traces, due to the different interaction profile of each tablet with the SGF 
medium. The overall profile of the three traces does, however, show similarities. Three 
distinct phases of interaction can be seen.
i. Small burst of swelling as the tablet begins to interact with the SGF within the 
first minute of the test.
ii. A rapid decrease in the size of the tablet that continues for the first hour of the 
test.
iii. A further, slower degeneration of the tablet that continues until the end of the 8- 
hour test run.
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0 2.1711 2.1711 2.1711 2.1711 0.0000
1 2.1435 2.1855 2.2727 2.2006 0.0659
15 1.9623 1.9628 1.919 1.9480 0.0251
30 1.7756 1.8530 1.726 1.7849 0.0640
45 1.6417 1.5761 1.5345 1.5841 0.0540
60 1.5169 1.4824 1.4329 1.4774 0.0422
90 1.3988 1.3633 1.2996 1.3539 0.0503
120 1.2511 1.2052 1.1392 1.1985 0.0563
150 1.1388 1.1492 0.9765 1.0882 0.0968
180 1.0695 1.0815 0.9103 1.0204 0.0956
240 0.9157 0.9279 0.7457 0.8631 0.1018
300 0.8024 0.7630 0.6707 0.7454 0.0676
360 0.7180 0.6932 0.5916 0.6676 0.0669
420 0.5417 0.6257 0.5044 0.5573 0.0621
480 0.4569 0.5324 0.3958 0.4617 0.0685
The mechanisms involved in the swelling process have been discussed previously 
on page 121. However, the swelling is less pronounced than in previous blends, which was 
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5.7.4 Discussion of blend 4 characteristics
So far the characteristics of the tablets from blend 4 have been investigated and 
discussed on an individual test basis. This section aims to compile these results to explain 
the mechanisms of the tablets in vitro floating properties, in order to understand the 
behaviour of blend 4 as a floating dosage form. The data will enable assessment of the 
importance of the individual features that allow blend 4 to float successfully for the 8-hour 
period.
As discussed previously the tests that have been conducted fall into two main 
categories:
1) Initial dry tablet characterisation
2) Dynamic wet tablet characterisation
The aim was to produce tablets with an average weight of 1.44g and an 
approximate hardness of between 17-18KPa. The tablets that were produced had an 
average weight of 1.4389g, with a standard deviation of 0.0012, and an average hardness 
of 18.64KPa, with a standard deviation of 0.555. These ranges were deemed to be 
appropriate for the studies.
The second part of the dry tablet characterisation was concerned with the surface 
area and pore size distribution of the tablets. The tests showed that the tablets from blend 4 
had a relatively small surface area. It is thought that the relationship between initial 
surface properties and dynamic properties in this blend are not very strong, due to the rapid 
changes that the tablets undergo once they are submerged in SGF. The tablets undergo a 
dramatic change in structure that is more due to the blend formulation than the initial pore 
size / surface area.
The dynamic stage of testing is the most relevant to this work. Three different tests 
were performed to study the factors that lead to buoyancy; the resultant weight, the rate of 
gas production and the continuous swelling of the dosage form.
In order to fully understand the dynamic changes that are occurring within the 
tablet during testing, it is necessary to study the profile of the graphs that have been 
produced from the multiple runs. Figure 46, page 142, shows the average data from the 
three dynamic tests. The data sets have been normalised in order to show the data on the 
same axis. The buoyancy graph shows the average resultant weight exhibited, the swelling
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data shows the average for the five tablets, whilst the pressure data shows the average 
normalised gradient of the pressure built up in the pressure vessel. The pressure gradient 
was calculated using 90-second intervals throughout the duration of the test.
As expected, the buoyancy graph can be explained using the swelling and rate of 
gas release graphs. As discussed before the buoyancy profile of the tablets can be broken 
down into four main sections:
1. An initial peak buoyancy period as soon as the tablets are immersed in the SGF 
medium.
2. After the initial buoyancy period, a rapid decrease in buoyancy until approximately 30 
minutes has passed.
3. A second buoyancy increase then becomes apparent in the trace. This increase 
continues until approximately 3.5 hours after the start of the experiment.
4. After 3.5 hours, until the end of the test, the resultant weight is seen to decrease 
steadily.
These four distinct sections within the buoyancy profile occurred reproducibly for all 
tablets tested. The principles have been described previously for blend 2 and 3.
Having discussed the properties of each of the individual profiles created by blend 











Figure 46 A graph to show the normalised dynamic testing data sets for blend 4
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Three similar blends have been produced and analysed using the developed barrage 
of testing techniques. It has been shown that the techniques developed are capable of 
explaining the buoyancy effects of a particular dosage form. This section will compare the 
three blends to see if the dynamic methods are capable of distinguishing between tablets 
produced with slightly different blend excipients. The constituents of each blend are 
shown below in Table 30, page 143.
Table 30 Comparison of blend constituents
Excipient Blend 2 Blend 3 Blend 4
(mg per tab) (mg per tab) (mg per tab)
Ciprofloxacin 1000 800 1100
Sodium Alginate 5 5 5
Xanthan Gum 15 15 15
Sodium Bicarbonate 200 400 100
XLPVP 177 177 177
Magnesium Stearate
Intra-granular 26 26 26
Inter-granular 7 7 7
Talc 10 10 10
Total Weight 1440 1440 1440
5.8.1 Comparison of buoyancy results
The three blends that were tabletted consisted of varying levels of sodium 
bicarbonate in the formulation, at the expense of ciprofloxacin. The ciprofloxacin was 
removed from the formulation to accommodate the extra sodium bicarbonate because it 
was thought that the drug itself had the least effect of all tablet constituents on the floating 
properties of the formulation.
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Each formulation was tested five times in the buoyancy apparatus and the average 
buoyancy profile for each formulation was calculated. The average profiles are shown in 
comparison in Figure 47, page 146. It can be seen from the graph that all the formulations 
produced a similar buoyancy profile and all floated for the duration of the 8-hour test 
period. Common characteristics of the buoyancy profile were:
1. A sudden rapid increase in buoyancy during the first few minutes of testing.
2. A decrease in buoyancy which occurred between the 10-30 minute period.
3. A second increase in buoyancy, culminating in a peak between the 30-90 minute period 
(less marked for blend 4).
4. A slow decrease in buoyancy that lasts until the end of the 8-hour test.
We can see from the profiles that the blend with the least sodium bicarbonate 
(blend 4) also yields the lowest resultant weight at all times during the test. This is to be 
expected due to the direct link between gas generated and trapped within the polymer 
network and density. When the amount of sodium bicarbonate is doubled in the 
formulation (blend 2) it yields more than a 2-fold increase in buoyancy effect throughout 
the duration of the test. This increase in buoyancy would lead to the dosage form being 
more likely to float in a more viscous medium. As in vivo the viscosity of the stomach 
contents will vary depending on food content it is more likely that blend 2 will stay afloat 
on the contents on the human stomach than blend 4.
In blend 3 the amount of sodium bicarbonate has again been doubled, however this 
does not result in a 2-fold increase in buoyancy over blend 2 on this occasion. It can be 
seen in Figure 47 that blend 3 does exhibit an increased buoyancy effect during the first 
three phases of the profile. However, it is also noticeable that these three phases occur 
over a shorter time period than for the other blends. After approximately 2-hours of the 
run it is seen that blend 3 actually becomes less buoyant than blend 2, despite having a 
higher bicarbonate content. It appears this is a direct result of the formulation breaking up 
due to the increased bicarbonate level exhibiting a greater disintegrant action.
We can therefore say that blend 2 would be the optimum blend if a formulator was 
looking to achieve floating in vivo over an 8-hour period, whilst if a shorter floating period 
was needed then blend 4 may be the formulation of choice.
It is also noticeable from the graphs that as the amount of bicarbonate in the 
formulations is increased, so the degree of fluctuation in the average traces increases. This
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fluctuation is a result of gas bubbles escaping from the polymer matrix of the tablet, and 
buoyancy suddenly being lost.
It has been shown that the buoyancy apparatus developed is capable of 
distinguishing the differences between similar formulations. The apparatus could therefore 
be used in future work to assess in vivo candidates prior to testing. It would also be 
possible to study previous work in order to investigate explanations for in vivo failures. 




























5.8.2 Comparison of pressure vessel results
Each formulation was tested five times in the pressure vessel and the average 
pressure profile for each formulation was calculated. The average profiles are shown in 
comparison in Figure 48. All profiles are characterised by a rapid gas release during the 
first minutes of testing as the tablets initially react with the simulated gastric medium. 
There then follows a momentary pause in gas release as the tablets stabilise in the medium, 
prior to a secondary phase of gas release that continues until the end of the test.
It can be seen from the profiles that the formulation with the least sodium 
bicarbonate (blend 4) exhibits the slowest rate of gas release, as expected. In fact the rate 
of gas release increases in direct correlation with increasing levels of sodium bicarbonate 
content in the formulation.
The blend with the most sodium bicarbonate present (blend 3) released gas so 
rapidly that the calibration limits of the pressure vessel were soon exceeded. In order to 
assess the rates of gas release further the pressure generated per hour was calculated for 
each blend. The results are shown below in Table 31. One way ANOVA performed on 
the original average pressure generated per hour data indicated that the sample means were 
significantly different.
The pressure generated for blend 2 is approximately twice that of blend 4, which 
was expected before the test. However the rate of gas production for blend 3 is more than 
twice that of blend 2. This is because the blend 3 tablets exhibit their optimum gas release 
during the first 2 hours of testing, as seen in the buoyancy graphs. If the pressure release 
could have been monitored for the entire 8-hour period it would have been expected that 
the rate of gas release for blend 3 would have decreased dramatically.
It has been shown though that the apparatus is capable of reproducibly detecting the 
differences between formulations produced with varying levels of excipients. The rate of 
gas release and total gas production exhibited by a formulation has been shown to be 
vitally important when assessing the intrinsic properties of floating dosage forms. This 
apparatus can therefore be used to assess future candidates for gas-powered floating dosage 
forms in order to optimise their in vivo floating properties. The results of these tests can be 
used in conjunction with the buoyancy testing results to assess the effect that variations in 
gas release rate have on buoyancy over extended periods.
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Table 31 Average pressure generated per hour for test blends




5.8.3 Comparison of swelling results
Each formulation was tested three times in the swelling apparatus and the average 
swelling profile for each formulation was calculated. The average profiles are shown in 
comparison in Figure 49. All profiles follow a distinctive pattern whereby the peak 
swelling is achieved in the first minute of testing. The tablets then erode away until the 
end of the test. The peak mean swelling size for each blend is shown in Table 32, page 
151.
The profiles show that the blend with the least sodium bicarbonate (blend 4) also 
exhibits the least swelling. This was expected, as the extra bicarbonate in the blend acts as 
a disintegrant for the tablets, therefore increasing the surface area. This also helps explain 
why the buoyancy for blend 4 is reduced, as a decreased surface area will lead to an 
increased density.
Blend 3 (maximum sodium bicarbonate content) exhibits the most swelling, 
however it can be seen after approximately 2.5 hours, until the end of the test, the 
difference between blend 3 and blend 2 is minimal. This would help to explain why the 
buoyancy of blend 3 is at its peak during the first 2 hours of testing.
One way ANOVA was performed on the mean peak swelling size data, which 
indicated that there was a significant difference between all data sets.
It has been shown therefore that the swelling apparatus is capable of distinguishing 
between blends made from similar excipients, and that the results can be used to explain 
the floating properties of the formulations. The apparatus could be used along with the 
buoyancy apparatus and the swelling vessel to assess the effect of changing excipient 
parameters on buoyancy. Once the effect of different parameters are understood it is 
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Table 32 Peak swelling size comparison for test blends





Three methods and apparatus have been developed capable of identifying and 
quantifying the parameters associated with gas-powered floating dosage forms.
A buoyancy test has been developed that enables constant assessment of buoyancy 
over a predetermined test period. The test allows determination of the dynamic 
interactions occurring between the dosage form and the test fluid.
A method and apparatus capable of quantifying the amount of gas released from a 
dosage form over a period of time has also been developed. The pressure vessel has been 
shown to be capable of distinguishing between similar formulations. It has also been 
shown that the pressure vessel results can be used to partly explain the results seen in the 
buoyancy apparatus.
A further technique has been developed that enables assessment of the swelling of a 
dosage form. The swelling of floating tablets has been shown to be of importance when 
trying to establish why a dosage form exhibits particular buoyant properties.
The amount of sodium bicarbonate is of importance for floating dosage forms. 
However, an increase in the amount of bicarbonate does not always result in increased 
buoyancy. The three dynamic methodologies could however be used to optimise the 
amount of bicarbonate required in a formulation in order to achieve a desired floating 
profile.
It is possible that the three methodologies can also be used in unison to assess 
previous in vivo test results in order to explain previous discrepancies.
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CHAPTER 6 
CASE STUDY OF A FLOATING SYSTEM (1)
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A study was conducted to assess whether the developed apparatus were capable of 
testing a non-tablet formulation. All previous work had thus far been conducted using 
tablets that generated a significant amount of carbon dioxide in order to achieve their 
buoyancy. This case study looks at an aerogel capsule system that had been developed to 
have a density of less than that of water, and which will therefore, once swallowed, float 
on the contents of the stomach for a prolonged period of time (Patent number WO 
0110419). Carvedilol was used as an example of a low-dose drug that has site-specific 
absorption in the small intestine.
6 .1 Manufacture of the aerogel system
The aerogel capsules were manufactured according to the qualitative composition 
in Table 33, page 153.
Table 33 Qualitative composition of aerogel capsules
Material Manufacturer Batch number
Carvedilol Cadila healthcare 9CD003
Glucidex 40D Rouquette 65081
Xanthan gum Monsanto 8J0370K
Emcocel 90M Mendell 9S6005
Ammonium bicarbonate BDH -
Calcium carbonate (heavy) BDH -
Lubritab Mendell 666812603
Method:
1. Emcocel 90M, glucidex and xanthan gum are sifted through a 40-mesh sieve and 
mixed for 30 minutes in a turbula mixer.
2. The Carvedilol and calcium carbonate are passed through a 40-mesh sieve and the 
ammonium bicarbonate and lubritab are passed through an 85-mesh sieve. These 
components are then mixed with the blend from step 1 for another 30 minutes using a 
turbula mixer.
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3. The blend was then left overnight, before being filled into size 0 gelatine capsules.
4. The capsules were treated at 80°C for 35 minutes before being cooled to room 
temperature.
6.2 Buoyancy testing
Five capsules were tested in the buoyancy apparatus to assess the floating force 
properties of the aerogel system. The capsules were tested using the method outlined 
previously in section 3.8, page 33.
The results are shown graphically in Figure 50, page 155. The graphs show that all 
the aerogel capsules floated for the duration of the 8-hour test. The resultant weight 
generated by the capsules varied between 0.5 and 0.15g. All capsules showed a similar 
buoyancy profile, with a slight variation between the maximum buoyancy achieved. It was 
thought that this slight variation was due to small variations in the quantity of ammonium 
bicarbonate present in the capsules. In previous experiments fluctuations in the resultant 
weight have been seen that were thought to be the escape of gas from the formulation 
leading to a sudden loss of buoyancy. When using aerogel capsules the degree of rapid 
fluctuation is much reduced and only seen at the start of some capsule runs. This is due to 
the reduced sodium bicarbonate content of this formulation, with the “jumps” occurring 
due to the escape of gas from the inside of the capsule, as it begins to degenerate.
The average buoyancy profile is shown below in Figure 51, page 156. The profile 
shows that the average initial buoyancy of the capsules is approximately 0.2g. As soon as 
the capsules are submerged into the simulated gastric fluid, an increase in buoyancy is seen 
that reaches a peak after approximately 25-minutes of almost 0.4g. The resultant weight 
was then constant until 4-hours of the test had passed. After approximately 4-hours a 








































The graphs were assessed for reproducibility by measuring the area above each 
individual curve, as a measurement of the buoyancy force exhibited by each capsule 
throughout the duration of the experiment. Peakfit 4.06 for Windows was used to analyse 
the data sets and to produce the buoyancy force data shown in Table 34, page 157. The 
capsules showed a mean buoyancy force of 2.4190gh during the experiment, with a 
standard deviation of 0.28569. These values were deemed to be within the desired range 
for the purposes of the test.
Table 34 A table to show the buoyancy force data for aerogel capsules








6.3 Pressure vessel testing
Five aerogel capsules were tested in the pressure vessel to assess the rate of carbon 
dioxide production from the formulation. The capsules were tested using the method 
outlined previously in section 4.9.1, page 58, with the capsule being added to the release 
mechanism before the vessel was sealed, and the capsule released into the medium after re­
zeroing via the pressure vent.
Results of the five capsule runs are shown in Figure 52, page 159. The graph 
shows the data sets from the re-zero point onwards until the end of the test. The five runs 
show a similar profile of carbon dioxide release throughout the duration of the test. There 
is a small variation in the total gas released from each capsule, but this is to be expected
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due to the inherent variability in the manufacturing procedure. However, all graphs follow 
the same reproducible profile.
Immediately after immersion no gas is produced from the capsules, as a direct 
consequence of the protective coating forming a barrier around the active formulation. 
After a few minutes this coating begins to erode away and allowing the gastric fluid access 
to the bicarbonate present in the aerogel blend. The result of the interaction is a burst of 
CO2 , which then continues to be produced throughout the test. After the initial burst, the 
rate of gas production slows slightly until approximately an hour has passed. After the first 
hour of the test the rate of gas production then increases again, before continually slowing 
until the test has been completed. The rate of gas production decreases until the end the 
test due to the diminishing stable bicarbonate content in the formulation. Figure 53, page 
160 shows the average rate of gas release for the aerogel capsules.
Table 35, page 161, shows a summary of the data. It can be seen from the table that 
the capsules generated between 24.4 and 30.1 mbar of pressure throughout the duration of 
the experiment. The variation in pressure is due to the slightly different dynamic 
interaction of each capsule with the simulated gastric fluid, along with the inherent 
variation present in the formulation. The average pressure generated per hour for the 

















































1 26.59 7.31 3.64
2 24.41 7.31 3.34
3 30.06 7.31 4.11
4 25.60 7.31 3.50
5 25.29 7.31 3.46
6.4 Swelling studies
Three aerogel capsules were tested according to the protocol outlined in section
5.6.7.5, page 98.
Sample digital photographs from the study are shown below in Figure 54, page 
162. Table 36, page 163 shows the results of the image analysis for each run, along with 
average values. The data for time zero was taken by subjecting a dry control capsule to the 
image analysis process.
The data can be seen graphically in Figure 55, page 164. From the data it can be 
seen that all three runs show similar profiles. The runs do not follow identical traces, as 
each individual capsule has a slightly different interaction profile with the SGF medium. 
The overall profile of the three traces does, however, show similarities.
It can be seen from the graphs that initially the capsules shrink slightly, this is due 
to the initial interaction of the gelatine capsule with the SGF, which causes the gelatine to 
contract around the formulation as it begins to dissolve.
The capsules then swell rapidly until the 2-hour point. This swelling occurs once 
the gelatine capsule has been dissolved and ruptured, allowing the gastric fluid direct 
access to the previously dry formulation. The polymers in the formulation then hydrate 
rapidly making the capsule swell, whilst the sodium bicarbonate also interacts with the 
SGF to produce carbon dioxide. The carbon dioxide produced acts as a partial disintegrant 
and forces the tablet to expand to accommodate the gas.
The swelling process slows continuously from this point as the gastric fluid begins 
to erode away the capsule front. After six hours the capsule eventually starts to shrink as
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the rate of erosion of the capsule overtakes any further swelling. This erosion continues 
until the end of the test.
Figure 54 Sample digital photographs of the capsule swelling process
1 minute




















0 1.1256 1.1256 1.1256 1.1256 0.00000
1 1.0849 1.0707 1.0729 1.0762 0.00764
15 1.4297 1.4515 1.5395 1.4736 0.05813
30 1.5854 1.6973 1.7567 1.6798 0.08698
45 1.6564 1.8642 1.8971 1.8059 0.13051
60 1.9740 1.9193 1.9661 1.9531 0.02957
90 2.0525 2.1356 2.0991 2.0957 0.04165
120 2.2053 2.2441 2.2548 2.2347 0.02604
150 2.2260 2.4455 2.2564 2.3093 0.11893
180 2.3190 2.5130 2.2670 2.3663 0.12965
240 2.5026 2.6232 2.3252 2.4837 0.14990
300 2.6944 2.6105 2.3846 2.5632 0.16023
360 2.6343 2.6088 2.4128 2.5520 0.12119
420 2.5030 2.4228 2.3809 2.4356 0.06204


























6.5 Discussion of the aerogel capsule characteristics
The characteristics of the aerogel capsules have been investigated and discussed on 
an individual test basis. This section aims to compile these results together so that the 
mechanisms of the in vitro floating properties can be explained, in order to understand the 
behaviour of the capsules as a floating dosage form. The data will enable us to assess the 
importance of individual features that allow the formulation to float successfully for an 8- 
hour period.
The three different tests were performed to study the factors that lead to buoyancy; 
the resultant weight, the rate of gas production and the continuous swelling of the dosage 
form. These tests have previously been shown to be useful when analysing a gas-powered 
floating dosage form.
In order to fully understand the dynamic changes occurring within the tablet during 
testing, it is necessary to study the profile of the graphs that have been produced from the 
multiple runs.
Before looking at all the data together it is first necessary to assess the gas release 
data set. Figure 56, page 166, shows the normalised gas release data for the aerogel 
capsules. The pressure data shown is the average normalised gradient of the pressure built 
up in the pressure vessel (e.g. the normalised rate of gas release). The pressure gradient 
was calculated using 6-minute intervals throughout the duration of the test. A polynomial 
trend-line has been added to the graph in order to smooth the results and aid analysis.
Figure 57, page 169, shows the average normalised data from all the experiments. 
The data has been normalised so that all the data can be shown against the same axis. The 
buoyancy graph shows positive data, e.g. the average resultant weight exhibited by the 
tablets. The swelling data shows the average data for the five tablets, whilst the pressure 
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As expected, the buoyancy graph can be explained using the swelling and rate of
gas release graphs. The buoyancy graph can be broken down into three main sections:
1. An initial increase in buoyancy during the first 30-minutes of the following immersion 
of the capsules in the SGF medium
2. After the initial buoyancy period, an equilibrium period is found that enables the 
resultant weight to remain approximately constant until four hours have elapsed.
3. After four hours the buoyancy of the aerogel capsules begin to decrease. This decrease 
continues until the end of the test.
These three distinct sections within the buoyancy profile occurred for all capsules tested.
Listed below is an explanation of the changes the capsules undergo during the floating
process, with each step being used to explain the three sections of the buoyancy profile that
are seen:
1. The graphs show that the initial buoyancy increase is a combination of capsule 
swelling and gas production. Capsule swelling leads to an increase in buoyancy due to 
the intrinsic relationship present between volume and density. Gas production adds to 
the buoyancy increase because some of the gas produced will remain trapped within 
the polymer network of the capsule. As the aerogel capsule swells however, it is 
expected that some of the intrinsic buoyancy effect conveyed by the initial aerogel 
structure will lessen.
2. After about an hour the rate of gas release from the capsule becomes approximately 
constant. During this time the capsule continues to swell due to a combination of the 
polymers continuing to hydrate and the CO2 forcing the capsule to expand. During this 
time the buoyancy of the capsules is seen to remain constant. It is thought that the gas 
being released is enough to sustain the buoyancy that is partially lost through the 
destruction of the aerogel structure.
3. The final phase on the graph shows a continuous decrease in buoyancy until the end of 
the test. We can see during this phase that the rate of gas production is also starting to 
decrease proportionally. We can also see that the capsules have stopped swelling and
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are actually beginning to erode. It is the combination of these negative factors that 
result in the decrease in buoyancy that is seen. It should be noted that the capsules are 
still buoyant until the end of the 8-hour test period despite the decreasing trend.
It has been shown in the discussion above that the combination of methods used is 
an effective means of understanding the buoyancy profile of the capsules. It has also been 
shown that the developed methods can be used for either tablets or capsules.
The main difference between the aerogel capsules and the previous tablet 
formulations is the effect that swelling had on the buoyancy profile. This is due to the 
inherent difference between the initial properties of the formulations. The tablets relied on 
the generation of gas and an increase in volume to achieve buoyancy, whereas the aerogel 
capsules were formulated to be buoyant before any interaction with the SGF had taken 
place. This results in the buoyancy of the aerogel capsule formulation being, at times, 
adversely affected by swelling. It was thought this was due to the buoyant aerogel 
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CHAPTER 7
CASE STUDY OF A FLOATING SYSTEM (2)
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Studies have previously shown unexpected discrepancies between in vivo and in 
vitro results when using floating dosage forms. Due to the lack of in vitro testing 
mechanisms available, the exact reasons for some in vivo failures occur have not been 
determined. This study will look at an omeprazole capsule formulation that was shown to 
have unexpected in vivo results, before trying to establish the reason for the discrepancy.
7.1 Discussion of in vivo results
The omeprazole capsules (Ranbaxy, India) being tested (European patent number 
0960620) were formulated as a generic equivalent to Losec 20mg capsules (Astra-Zeneca, 
London, UK). Omeprazole is a proton pump inhibitor that is degraded by the acid 
conditions found in the stomach. It is therefore necessary for an omeprazole system to 
have some degree of enteric coating that protects the drug from the acidic conditions of the 
stomach. Both of the formulations in the study utilise enteric coating, but in different 
ways. The generic capsule (Ranbaxy) enteric coating covers the entire capsule, whilst the 
Losec capsule (Astra-Zeneca, London, UK) enteric coating covers many individual 
microcapsules within the main capsule surround.
The previous in vitro work on the generic capsules had centred on achieving bio­
equivalence with the Losec capsules. The dissolution results shown below in Table 37, 
page 171 were conducted using a USP 2 method at lOOrpm and a pH of 6.8. The capsules 
were all pre-tested for 2-hours in 0.1M HC1 to ensure the stability of the enteric coatings.
Table 37 Comparative dissolution results for Omeprazole formulations
Time (min) 0 15 30 45
% released 
(Losec)
0 80.4 85.2 86.9
% released 
(Generic)
0 29.0 87.0 92.0
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The results show that the enteric coating protects the drug from the 0.1M HC1 in 
both formulations. The results also show that over 85% of omeprazole had been released 
after only 30 minutes of testing in the 6.8pH medium. This indicated that once the 
capsules passed the stomach in vivo the formulations would display similar release 
profiles, leading to bio-equivalence.
The capsules were then tested in an in vivo study, using 23 people (Study number 
100/98, Ranbaxy, India). All participants were under fasting conditions so that the 
stomach was empty during testing. Table 38, page 172 shows the results of the in vivo 
study.
Table 38 Comparative in vivo Cmax values of omeprazole formulations
Cmax (ng/ml)
Geometric mean (Losec) 454.6
Geometric mean (Generic) 371.7
Cmax ratio (Generic/Losec) 81.76
The results of the study show that the Cmax of the generic formulation was much lower 
than that of the Losec formulation. This result was unexpected after the previous 
equivalent dissolution results. It is possible that some of the generic capsules were being 
retained in the stomach for longer than expected and therefore undergoing degradation in 
the acid conditions as the enteric coating fails. In order to test this theory, the capsules 
were tested in the buoyancy apparatus.
7.2 in vitro buoyancy resuits
Five generic capsules were tested in the buoyancy apparatus to assess the floating 
force properties of the aerogel system. The capsules were tested using the method outlined 
previously in section 3.8, page 33.

























The graphs show that all of the generic capsules floated for the duration of the 8- 
hour test period. This was an unexpected result, as it was initially thought the capsules 
would not float for long periods. It is obvious that a floating capsule will be retained in the 
stomach for longer periods in some patients, but this would not cause much of a problem 
as long as the enteric coating remained intact.
Two of the graphs exhibit a sudden decrease in buoyancy after approximately five 
and a half hours. This sudden decrease is thought to be the release of a gas bubble from 
the capsule, which indicates that the enteric coating of the capsule has failed. This 
supposition was backed up by examination of the capsules after the test had concluded.
The two capsules that were shown to exhibit a sudden decrease in buoyancy were the only 
capsules not intact after completion of the test. This indicates that there is a high degree of 
variation in the coating level of the capsules, resulting in some of the capsules remaining 
intact throughout the test and some of the capsules rupturing. If the capsules were to 
rupture in the stomach during the in vivo testing, the active omeprazole would be degraded 
by the acidic conditions, resulting in decreased Cmax blood levels. As this failure of the 
coating occurs after five and a half hours, it would not have caused a problem during the in 
vivo testing if the capsules had not floated. It is the floating of the capsules that will 
prolong the residence time in the stomach, thereby enabling the enteric coating to rupture, 
leading to degradation of the active drug. This variation in coating would not have been 
detected in the in vitro dissolution work because the acid pre-test only lasted for two hours.
7.3 Conclusions
The buoyancy apparatus has been used to help us to understand the problems that 
can be associated with in vitro -  in vivo correlation. It has been shown that the apparatus, 
when used in conjunction with visual inspection, can explain in vivo results that were 
previously not understood. If the buoyancy apparatus had been used before the in vivo 
work had been performed, it would have been possible to predict the failure of the trial. 
Work could then have focused on finding a way around the floating/coating problem, 






The aims of this project were to develop and test various novel in vitro apparatus 
capable of identifying, and optimising, the vital characteristics of floating dosage forms.
The rational design of in vitro experiments is essential for the thorough 
understanding of any dosage form. It is perhaps even more important when considering 
the various intrinsic factors that influence the ability of a formulation to float. Floating 
dosage forms, in particular, have been shown to have a low degree of in vitro -  in vivo 
correlation, hence there is a real need for apparatus capable of accurately predicting the 
behaviour of such dosage forms in vivo.
The most important factor to consider when designing floating dosage forms is the 
ability of a formulation to float upon the gastric fluids. It is not enough, however, to take a 
pre-testing density reading as an indicator of a dosage forms ability to float, as this does 
not take into account the many dynamic interactions that occur between a formulation and 
a test medium during testing. It is also unsatisfactory to simply state whether a dosage 
form floats or not, as it is much more preferential to quantitate the force with which a 
formulation is floating. This gives the formulator an idea of the robustness of the dosage 
form, and an indication as to what to expect when confronted with different stomach 
conditions in vivo.
A buoyancy apparatus was therefore developed that was capable of quantitating the 
dynamic floating profile of a dosage form over a functional time period. The apparatus 
consisted of a temperature regulated water bath linked via a force transmitter device to a 
computer for data logging. It has been shown that the apparatus can distinguish between 
the floating profiles of slightly modified formulations, helping the understanding of the 
dynamic interactions that are occurring within a dosage form during testing. The technique 
has been used to assess both gas powered and aerogel formulations successfully. Finally, 
the apparatus has been used to assess an in vivo failure and to explain the reasons for the 
lack of clinical success.
An integral part of many floating dosage forms is the ability to either trap or 
generate gas to aid buoyancy. Understanding and controlling the rate of gas release from a 
dosage form would enable the formulator to tailor a dosage form to meet their needs. A 
pressure vessel has therefore been designed and developed, that is capable of accurately
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measuring the rate and extent of gas evolution from a floating system. The glass vessel is 
temperature regulated and linked, via a calibrated pressure transducer, to a personal 
computer for data logging.
It has been shown that the pressure vessel is capable of distinguishing between the 
gas release profiles of similar dosage forms. The rate of gas release has been used, along 
with the results from the buoyancy apparatus, to explain the buoyancy profiles seen for 
particular dosage forms. The apparatus has successfully measured gas-powered and 
aerogel floating formulations.
The third parameter associated with the floating ability of a dosage form is 
swelling. Density is inversely proportional to the volume of a dosage form, therefore if a 
tablet swells when immersed in medium, so the density of that dosage form will decrease 
correspondingly, hence aiding buoyancy.
A method that enabled real time quantification of the swelling of a floating dosage 
form was therefore developed. The apparatus consisted of a temperature regulated water 
bath, situated below a digital camera. Images from the camera were taken at pre­
determined intervals and then subjected to an image analysis process to determine 
swelling/erosion. The method was shown to successfully produce a dynamic swelling 
profile and to identify the differences between similar formulations. The results were used, 
in conjunction with pressure vessel data, to explain why a particular buoyancy profile was 
seen for a particular formulation. The apparatus was shown to successfully measure gas- 
powered and aerogel floating formulations.
The amount of sodium bicarbonate has been shown to be of importance for floating 
dosage forms. However, an increase in the amount of bicarbonate does not always result 
in increased buoyancy throughout the duration of a test. The three dynamic methodologies 
could however be used to optimise the amount of bicarbonate needed in a formulation in 
order to achieve a desired floating profile.
The three dynamic apparatus have been shown to be most useful in unison, in order 
to explain the characteristics of a floating dosage form. It would be possible to use the 
information to tailor a formulation to produce a desired floating profile under chosen 
conditions. The combined results from the apparatus would also enable the formulator to 
understand the likely results of any in vivo tests, without the need to waste time and money 
conducting such tests. It is the scientific understanding of the mechanisms that lead to the 
floating of a dosage form which will enable the production of better formulations, therefore
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the developed apparatus could play an integral part in the future development of floating 
dosage forms.
8.2 Further work
Having developed apparatus capable of identifying and accurately quantifying the 
parameters that influence the floating profile of a dosage form, further work should 
concentrate on the development of a novel gas-powered formulation. The dynamic testing 
methodologies should be utilised to develop and optimise the formulation, as well as to 
understand the interactions that occur during testing.
The optimised dosage form should then ideally be used in an in vivo study utilising 
gamma scintigraphy to study the position of the dosage form in the stomach. The in vitro 
testing should also be conducted after addition of the gamma emitter in order to assess the 
potential impact upon buoyancy parameters.
One in vivo failure has already been explained using the apparatus. Work by other 
authors in the literature should be investigated to assess the reasons for their lack of in vitro 
-  in vivo correlation. Work should concentrate initially on gas-powered dosage forms.
Apparatus have been developed that measure buoyancy, swelling and gas 
production. One further parameter that should be investigated is the gel strength produced 
during swelling. Gel strength will have a direct effect on the ability of a formulation to 
trap any gas produced as well as on the dissolution parameters of the formulation. The 
development of a dynamic gel strength test would enable the formulator to have control 
over a further parameter that will have an effect on floating properties. Some work has 
been conducted in this area by Yang et al (1998) using a texture analyser (Stable Micro 
Systems, Surrey, UK). This method could possibly be adapted to measure the strength of 
the polymer gel layer that some floating dosage forms produce.
The effect of different mediums in the dynamic testing apparatus should also be 
investigated. Conditions in the stomach are not always identical, so the effect of changing 
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